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Abstract 
Scientists of today are posed with the challenge of engineering and the characterisation of 
nanoscaled objects which have been shown to be highly promising for new-age materials/devices 
as well as deepening our understanding of many natural systems. This thesis reports on the 
development of self assembling (cyclic peptide)-polymer conjugates, a versatile supramolecular 
route to complex nanostructures. 
A variety of conjugates were synthesised by a convergent strategy, using microwave assisted 
copper(I)-catalysed azide-alkyne cycloaddition to covalently couple alt(D,L)-α-cyclic peptides 
with synthetic polymers. Intermolecular association of the cyclic peptides forms cylindrical 
antiparallel β-sheets which drive the conjugates to form nanotubes with a polymeric shell. Herein 
we demonstrate the influence of polymers, peptide functionality and solvent conditions to 
manipulate the product of self assembly, characterising the assembly in solution using small 
angle neutron scattering (SANS). In H-bond competitive solvents, the inclusion of tethered 
polymers was found to stabilise and promote nanotube formation. Furthermore (cyclic peptide)-
polymer conjugate nanotubes could be obtained with lengths > 110 nm and as short as 10 nm by 
the variation of solvent conditions. Despite the strong influence of the tethered polymers on the 
product of self assembly, the functional groups on the peptide side chains were also found to 
influence nanotube solubility and/or decrease conjugation efficiency (as a result, increasing the 
lateral aggregation of the nanotubes). 
In a further investigation to control the lengths of the nanotubes, this thesis explores the 
potential of using partially N-methylated cyclic peptides (
NMe
CPs) as an associating motif to limit 
self assembly. While dependent on the tethered polymer, it was possible to observe, by size 
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exclusion chromatography, the dimerisation of monotopic conjugates, i.e. polymers that were 
functionalised with one 
NMe
CP at the α-terminus. In an extension of the system, ditopic 
conjugates were synthesised by the attachment of 
NMe
CPs to both ends of telechelic polymers in 
order to drive the formation of main-chain supramolecular polymers. Given the association 
constant determined for the 
NMe
CP (Ka = 1700 M
-1
), a low degree of polymerisation and a highly 
dynamic assembly was expected. Instead we have observed, through differential scanning 
calorimetry, light and neutron scattering, the formation of large (~400 nm) extended structures 
with small (~1 nm) domains which we attribute to lateral aggregation of the cyclic peptide. 
Having established the self assembly behaviour of 
NMe
CP-polymer conjugates, we then 
explored the ability to ‘cap’ nanotube forming (cyclic peptide)-polymer conjugates, with the 
intention of controlling the nanotube length and adding functionality to the tube ends. Even at a 
molar ratio of 1:4 ([CP]/[
NMe
CP], 80 % 
NMe
CP) no change to the geometry of the assembly could 
be observed by SANS. To gain insight into this discrepancy, we have developed a 
thermodynamic model to describe the influence of monotopic species on an otherwise isodesmic 
assembly of ditopic species. This model predicts a significant decrease in the degree of 
polymerisation of the assembly at the concentrations we tested, disagreeing with our findings. 
We have reasoned that the disparity is due to the aggregation of 
NMe
CPs which consequently 
removes interaction with the nanotube and is inefficient for controlling the nanotube length.  
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1 Introduction 
1.1 Supramolecular chemistry 
Nanoscience is the study and manipulation of objects with sizes that are in the order of 1 to 
100 nm in one or more dimensions. Objects with nanostructures have become increasingly 
desirable and important case studies in many fields such as materials,
[1-4]
 molecular electronics,
[5]
 
catalysis,
[6] 
medicine,
[7]
 and biochemistry.
[8-11]
 One of the challenges in this area relates to the 
engineering and characterisation of nanoscaled objects. 
“Top-down” approaches, such as lithographic techniques,[12] have been refined over the years 
to continually access smaller length scales, mostly as a consequence from the demand for 
increases to the density of transistors for electronic components,
[13]
 but also for applications such 
as ‘lab-on-a-chip’ devices. Advanced techniques permit lateral structures with sub-100 nm 
features,
[14]
 but problematically, progress is plateauing due to the increasing difficulty to 
approach nanometer length scales because of fundamental limitations of the techniques 
employed, such as diffraction.
[15]
 Traditional “bottom-up” synthesis approaches that rely on 
covalent bonds have also come a long way, and total synthetic routes to highly complex, 
functional and well defined compounds show how far organic chemistry has progressed.
[16,17]
 
One notable feat by Schlüter et al. demonstrates the capabilities of our current covalent-based 
chemistries in realising ‘large’ nanostructures, by synthesising the largest covalent 
macromolecule (200 MDa) to date through a “crude” synthetic approach.[18] On the other hand, 
covalent polymerisation routes allow for the simple manufacturing of objects, that can overlap 
onto the nanoscale, but compromises with less well-defined products. Between the “top-down” 
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and traditional “bottom-up” approaches we are presented with an obvious gap in the difficulty to 
access well-defined objects of sizes between 10 to 1000 nm. 
Supramolecular chemistry offers an elegant means to bridge this size gap, between molecular 
and microscopic structures, to synthesise nanostructures.
[19,20]
 The definition of supramolecular 
chemistry, largely attributed to Jean-Marie Lehn, is the study ‘beyond the molecule’:[21,22]  
“Just as there is a field of molecular chemistry based on the covalent bond, there is a field of 
supramolecular chemistry, the chemistry of molecular assemblies and of the intermolecular 
bond.”[23]  
The notion of designing and developing combinations of non-covalent (and/or reversible-
covalent bonds)
[24]
 has the potential to create complex, well-defined and highly functional 
structures at the nanometer scale.
[25]
 This potential is evident by looking at nature where complex 
systems already exist in important biological processes, for example, in the transfer of oxygen by 
haemoglobin complexes, the photosynthesis cycle, the sodium-potassium pump, etc., all of 
which have inspired researchers.
[11]
 While nature is still the fore runner in nanoscaled systems, 
with many tasks difficult for us to replicate, the collective understanding and achievements in 
this field have nevertheless grown remarkably from the earliest synthetic achievements
[26,27]
 to 
more recent successes
[28-30]
 in manipulating molecular recognition. Conversely our growing 
knowledge continues to shed light on the mechanisms of natural systems, such as 
neurodegenerative diseases like Alzheimer’s disease.[31,32] 
In this thesis, we explore the use of (cyclic peptide)-polymer conjugates in which molecular 
recognition is programmed into the cyclic peptide motif, which then forms nanostructures by self 
assembly. In the remainder of Chapter 1, the rationale behind the usage and combination of self 
assembling cyclic peptides and polymers is surveyed. Chapter 2 describes our synthetic route to 
the conjugates. Chapters 3 and 4 demonstrate the self assembly as a consequence of modifying 
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the environmental conditions, cyclic peptide and/or tethered polymers, with Chapter 4 dedicated 
to the study of partially N-methylated cyclic peptides, an extreme modification of the cyclic 
peptide component which leads to drastically different products of self assembly. In Chapter 5, 
we combine the results from the previous chapters in an attempt to characterise the system, 
including a thermodynamic treatment, to understand and control the self assembly process. 
Finally concluding in Chapter 6 we discuss the future outlook that stems from this research. 
1.2 Self assembling cyclic peptides 
While there are a number of intermolecular interactions; namely, coordination bonds, 
hydrogen bonds, electrostatic, van der Waals, π-π, hydrophobic forces;[33] we will focus on 
exploiting H-bonding. H-bonds are directional, key to many biological processes such as the 
pairing of DNA and RNA strands and folding of proteins. While individual H-bonds are quite 
weak (4-60 kJ/mol),
[19,33,34]
 permitting reversibility in structures, the use of multiple H-bonds 
increases the association between recognition sites.
[35,36]
 More specifically, we have chosen to 
use the H-bonding of peptides, which allows the use of well-established chemistries for the 
synthesis and, with amino acids as building blocks, it is a versatile platform for tailoring 
functionality. 
Through theoretical studies in 1974, De Santis et al. recognised that cyclic peptides (CPs) 
with alternating D- and L- residues can adopt a conformation where hydrogen bonding sites are 
oriented parallel to the symmetry axis, promoting interannular associations in a cylindrical 
manner.
[37]
 Lorenzi et al. made early attempts to realise these tubular assemblies, where the 
synthesised CPs showed strong H-bonding in the solid state, but the need for trifluoroacetic acid 
to solubilise and analyse the samples also destabilised the H-bonds they were attempting to 
observe.
[38]
 Furthermore, single crystal x-ray analyses showed cocrystallised solvents and a lack 
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Figure 1.1: Electron microscopy and electron diffraction of bundled cyclic peptide nanotubes. Scale bars: 
(a) 1 μm; (d) 10 nm. Adapted from Ghadiri et al.[39] 
 
of associations between CP units.
[40]
 The experimental structure of the assembly remained 
inconclusive until 1993, where Ghadiri and coworkers employed pH sensitive residues to control 
the assembly and characterised the formation of nanotubes through the use of electron 
microscopy (Figure 1.1(a)-(d)), electron diffraction (Figure 1.1(e)), vibrational spectroscopy 
and crystal structure modelling.
[39] 
Since then, significant progress has been made studying cyclic peptides designed to be 
geometrically prearranged to adopt cylindrical β-sheets.[41] Alterations such as the number of 
residues, side chain functionalities, and/or incorporating β- or γ- residues in each CP unit are 
translated to the resulting supramolecular structure and reflect the modification. In turn this has 
spawned a large family of molecules, maintaining the characteristic ability to self assemble 
axially into nanotubes, which will be discussed in the context of design principles for obtaining 
the desired nanostructure:
[42] 
  
1 – Introduction 
5 
 
1.2.1 Self assembly 
The orientation of the hydrogen bonding sites parallel to the axis of the ring, leading to the 
equatorial protrusion of the amino acid side chains, allows the enthalpically driven assembly of 
CPs into extended tubular structures (see Scheme 1.1). The thermodynamics of CP assembly 
into nanotubes has largely been studied by the use of partially N-alkylated CPs (
Nalkyl
CPs). By the 
introduction of N-alkylated residues, hydrogen bonding can be restricted to one face of the cyclic 
peptide, limiting the assembly to dimers and permitting solubility in the assembled state. The 
equilibrium constant of dimerisation, Ka, is more easily studied than the association constants of 
the non-alkylated analogues, and has typically been measured by concentration-dependent 
1
H NMR spectroscopy in deuterated chloroform. The measured associations constants for 
alt(D,L)-cyclooctapeptides (Phe-Ala) are in the vicinity of 3000 M
-1
.
[43-45]
 Remarkably, if this 
represented the association of every cyclic peptide unit, it would not explain the formation of 
extended structures with microscopic lengths. The notable stability of non N-alkylated cyclic 
peptides despite the low Ka of their analogous dimers suggests a cooperative mechanism of 
assembly, in which the association constant for the initial stages of polymerisation (nucleation 
period) is not the same as the association constants for the growth, or elongation regime.
[46]
 It has 
been suggested that the conformational stabilisation of the peptide backbone and simultaneous 
formation of multiple non-covalent bonds is responsible for this cooperativity.
[47]
 Computational 
approaches are also useful to bring insight to the self assembly mode on a molecular level that 
reinforce and predict explanations of experimental observations.
[48-50]
 As a consequence, while 
very long assemblies can be obtained, the length of cyclic peptide nanotubes (CPNTs) cannot be 
easily controlled. However in a recent example, Mizrahi et al. illustrated the control over cyclic 
peptide nanotube growth through ‘layer-by-layer deposition’ of alt(D,L)--cyclic peptides on a 
gold surface. Through charge interactions of the lysine residues on one peptide and glutamic acid 
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Scheme 1.1: Classes of cyclic peptides that assemble into nanotubes through β-sheet interactions. (a) 
cyclic peptides with alt(D,L)-α-residues; (b) cyclic peptides with β-residues; (c) cyclic peptides with α- 
and γ-residues and; (d) self assembling heterocyclic peptides by incorporation of ε-amino acids. In all 
cases, the N-H and C=O hydrogen bond donors and acceptors are aligned with tube length. Note: Some 
side chains (R) have been omitted for clarity in the assemblies.
[42]
 
 
 
Scheme 1.2: Schematic depicting various design elements of CPNTs: (a) internal diameters can be tuned 
between 1-17 Å; (b) the external functionality of the CPNT can be tailored; (c) the functionality can be 
sequenced in a desired arrangement, elliptical nanotubes can be formed by sequencing γ residues to yield 
CPs with 2-fold symmetry; (d) the CP can be N-alkylated to add functionality or restrict assembly on one 
face; (e) the orientation of cyclic peptide nanotubes can be perpendicular or parallel to a substrate; (f) the 
internal chemistry of the cyclic peptide nanotube can also be modified by use of γ- or ε- residues.[42] 
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residues on the following peptide, control of the nanotube assembly was achieved.
[51]
 An 
alternative and interesting approach to controlling the lengths of assembly was also recently 
suggested by Granja et al., stemming from a molecular dynamics study of (α,γ)-CPs, the use of 
organochloride molecules in a highly H-bonding competitive solvent (such as water) would 
promote the association of the CPs around the guest molecule (i.e. enveloping the molecule in 
the core of the nanotube) and promote dissociation of the CPs beyond the length of the 
organochloride molecule.
[52]
 Also, it has been shown that the assembly length can be modified 
through the conjugation of polymers to cyclic peptides (see Sub-chapter 1.3 below). 
1.2.2 Synthetic approaches 
The availability of a large range of natural and novel amino acid building blocks and the 
ability to readily incorporate these into linear peptide sequences using standard peptide 
chemistry techniques (in particular solid phase peptide synthesis) enables fine-tuning of cyclic 
peptide structures for a variety of applications. For the nanotube forming peptides, high yielding 
cyclisation under dilute conditions is complemented by their propensity to aggregate and 
precipitate out of solution, thus facilitating purification and making it easy to increase the 
reaction scale. 
Literature provides a few unique variations that show the versatility of peptide chemistry. For 
instance, cyclising on resin has been used for combinatorial chemistry to establish libraries of 
materials.
[53,54]
 The advantages of the high throughput approach were demonstrated by screening 
the resulting materials for their antibacterial properties.
[54] 
In an alternative route, van 
Maarseveen et al. synthesised an azido-alkyne peptide precursor which was cyclised via a 
copper(I)-catalysed 1,3-dipolar cycloaddition. The cyclic peptide contained triazole heterocycles 
within the peptide backbone and was obtained in high yields.
[55] 
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1.2.3 Internal diameter 
The assembly of the cyclic peptide units allows sub-nanometer control over the van der 
Waals internal diameter of the hollow tube, a feature difficult to achieve in other tubular 
nanostructures. Through an increase or decrease of the total number of residues in increments of 
two amino acids at a time, the cyclic peptide ring size and therefore the internal diameter of the 
nanotube can be tailored to a certain point (Scheme 1.2(a)). In their pioneering work, Ghadiri 
and coworkers observed van der Waals internal diameters of 7-8 Å by cryoTEM, electron 
diffraction measurements and molecular dynamics for cyclo[-(D-Ala-Glu-D-Ala-Gln)2].
[39,56]
 
CPNTs have since been assembled from CPs with -amino acids (α-CPs) comprising four,[57] 
six,
[58-60]
 eight,
[39,54,59,61-68]
 ten
[69,70]
 or twelve
[71]
 residues resulting in internal diameters ranging 
from 2 Å up to 13 Å. Single crystal X-ray crystallographic data of N-methylated cyclic peptides 
(
NMe
CPs) with eight residues gave internal diameters of 7.5 Å which were consistent with the 
expected sizes of octameric cyclic peptide nanotubes.
[43]
 However, crystallographic evidence for 
the diameters of 
Nalkyl
CPs with more than eight residues were not obtained due to a lack of 
observable dimerisation, presumably due the lack of backbone rigidity in the 
Nalkyl
CPs.
[45]
 Dimers 
of hexameric
 Nalkyl
CPs were observed in the solid state in the case of cyclo[(-D-Leu-N-Me-
Leu)3]
[72] 
and cyclo[(-D-Leu-Leu)2-D-Leu-N-Me-Leu]
[72,73]
 but not in the case of cyclo[(-Phe-N-
Me-D-Ala)3].
[45]
 Instead, the correlation between residue number and internal diameter of a 
number of CPNTs was determined by molecular modelling.
[39,47,65,70,74]
 
1.2.4 ‘External’ functionality 
Introducing functionality is important to advance the nanostructure from a scaffold to an 
application. A major advantage of using self assembling CPs to form nanotubes is the ease of 
controlling the exterior functionality. As the side chain functional groups of the cyclic peptide 
project pseudoequatorially (Scheme 1.2(b)), functionality is provided by the wide range of 
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commercially available amino acids, and the sequence of the residues (Scheme 1.2(c)) 
determined by conventional peptide synthesis approaches. The early studies of the CP system by 
Ghadiri et al. exploited Glu as a pH trigger for the self assembly of CPs into CPNTs.
[39,61]
 
Applications of CPNTs as channels,
[61,64,66,69,70] 
antimicrobials,
[54,59,60,68]
 and sensors
[67]
 were 
achieved by employing non-polar amino acids, typically Leu and Trp, in the exterior of CPNTs 
to facilitate interaction with lipid bilayers. Non-polar amino acids (e.g. Ala, Leu, Phe) were also 
used to make N-alkylated cyclic peptide dimers soluble in non-polar, organic solvents. Sets of 
experiments that used these 
Nalkyl
CPs played a crucial role in elucidating the fundamental 
parameters of the self assembling CP system. Structures were obtained through X-ray analyses 
of single crystals and corresponded well to hypothesised structures.
[43,45,72,73]
 Conformational 
information and thermodynamics of the self assembly process such as association constants and 
enthalpic contributions could be studied by NMR techniques.
[43-45,73]
 
While N-alkylation prohibits self assembly on one face, it also provides the ability to place 
functionality on the face of the cyclic peptide unit (Scheme 1.2(d)). Sánchez-Quesada et al. used 
this feature by N-alkylating CPs to cap CPNTs in a lipid bilayer, to set up channel asymmetry 
and towards selective/gated ion transport.
[66] 
With a simple means to introduce functionality 
without disrupting the self assembly mechanism, it is possible to perform covalent chemistry 
through functional groups on the CPs. This provides access to a plethora of new structures based 
on directed synthesis. For example in work by Clark et al., specific alignments between 
ensembles of N-methylated cyclic peptides were “locked” by olefin metathesis of NMeCP 
containing homoallylglycine (Hag)
[75,76]
 and reversible disulfide formation of acetamidomethyl 
cysteine (Cys(Acm)).
[75] 
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1.2.5 β- and γ- residues 
Cyclic peptide assemblies can also be formed by peptides in which some or all of the 
α-amino acid residues are replaced with either cyclic γ- or chiral β-amino acid residues (Scheme 
1.1(c) and (b)). The use of such residues greatly expands the range of accessible CPNTs 
dimensions and properties. The introduction of cyclic-γ residues into the peptide sequence can 
greatly increase the strength of the assembly. While the γ-γ H-bonding interaction is not as 
strong as the α-α interaction,[77] the presence of the cyclic γ-residue rigidifies the peptide 
backbone compared to the more flexible α-CPs, resulting in much higher association constants. 
Indeed, many N-methylated CPs with α and γ-residues demonstrate association constants greater 
than 10
5
 M
-1
 in CDCl3,
[78,79] 
several orders of magnitude higher than all-α-CPs of similar 
sizes.
[43,45]
 This rigidity allows access to a much larger range of internal diameters than can be 
achieved with assemblies of α-CPs (Scheme 1.2(a)). Granja’s group have reported assemblies of 
CPs with α- and γ-residues ((α,γ)-CPs, Scheme 1.1(c)) containing four,[80] six,[81,82] eight,[78] 
ten,
[78]
 and twelve
[78]
 residues that possess internal diameters ranging from 1 to 17 Å. The ring 
size of the γ-residue is important in determining the strength of the assembly. Five membered 
rings, incorporated into the peptide using cis-3-aminocyclo-pentanecarboxylic acid (γ-Acp-
OH),
[78]
 result in more rigid structures than six membered rings, incorporated using 3-
aminocyclohexanecarboxylic acid (γ-Ach-OH),[77] and as such are more suited to forming 
peptides assemblies with large internal diameters. More recently Li et al. and Granja et al. have 
synthesised CPNTs from CPs containing all-γ residues.[83-85] 
In addition to altering the diameter of the peptide assembly, the introduction of cyclic amino 
acids allow for modification of the internal chemistry of the internal channel (Scheme 1.2(f)). 
α-CPs contain a hydrophilic pore,[86] often useful in their applications as ion channels, but 
modification of the chemistry of the interior requires replacement of the α-amino acid residues in 
such a way that it does not destroy the assembly. Kennedy et al. showed that the incorporation of 
1 – Introduction 
11 
 
hydrophilic amino acid residues in a predominantly hydrophobic cyclic peptide allows control of 
the chemistry of the cyclic peptide interior to be achieved.
[87]
 This approach results in a cyclic 
structure with the hydrophilic residues being confined to the interior of the cyclic peptide, 
whereas the exterior is hydrophobic. A similar strategy cannot be applied to the β-sheet forming 
cyclic peptides because the peptide conformation required for stacking positions all side chains 
(both hydrophilic and hydrophobic) on the exterior of the peptide macrocycle. Instead, several 
alternative methods have been devised to decorate the interior of the cyclic peptide. For instance, 
the alkane cycles present in (α,γ)-CPs increase the hydrophobicity of the internal channel without 
destroying the assembly, as demonstrated by the presence of chloroform in the pore, 
characterised by X-ray crystallography;
[82]
 γ-residues also provide a means to introduce 
functionality pointing into the core of the peptide assembly. Granja’s group first demonstrated 
this approach by using 4-amino-3-hydroxytetrahydrofuran-2-carboxylic acid (γ-Ahf-OH) to 
introduce a hydroxyl group into the core,
[88]
 and Xu et al. have more recently introduced a 
methyl group into the centre of the cyclic peptide ring by introducing 3-amino-2-methyl-benzoic 
acid (γ-Mba-OH) to an otherwise all-α-CP.[63] 
The inclusion of cyclic residues can also change the geometry of the internal channel, 
depending on how they are placed around the cyclic peptide ring. Ghadiri’s group demonstrated 
the use of synthetically simpler ε-amino acids to incorporate two triazole cycles into tetrapeptide 
ring and observed an elliptical pore roughly 5.2 Å  between the triazole rings and 6.8 Å across 
the perpendicular axis.
[86]
 Granja’s group observed similarly elliptical pores from eight 
membered CPs containing two γ-Ach amino acids (3.8 – 4.3 Å by 8.8 – 9.2 Å).[89] 
The chemistry of cyclic peptide nanotubes can also be altered by using chiral β-amino acid 
residues. The first assembling peptides composed solely of β-amino acid residues were 
investigated by Seebach et al.
[90-92]
 Due to the additional carbon atom in the backbone of each 
residue, multiple conformers of the CP can permit hydrogen bonding and strong tubular arrays 
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can be formed from peptides with and without the alternating chirality that is required for the 
assembly of α-CPs.[90] Notably, in contrast to the antiparallel β-sheet structures formed by 
alt(D,L)--CPS, assembly of β-CPs results in parallel β-sheet formation, giving rise to a tubular 
dipole moment which has proven beneficial in gating and ion transport applications.
[74,90]
 More 
recently a number of sugar containing β-CPs have been synthesised and shown to assemble into 
bundles of tubular arrays.
[93-96]
 Kimura and co-workers have demonstrated the binding of lectin 
to such a peptide in a double assembly, resulting in the formation of a protein nanotube after 
crosslinking of the lectin.
[95]
 
1.2.6 Orientation 
Due to the anisotropy of nanotubes, it is crucial to understand and control their orientation 
with respect to their surroundings for applications. It has been found that the orientation of the 
cyclic peptide nanotube with respect to a surface can be controlled by the presence and absence 
of lipid matrix (Scheme 1.2(e)). In tailoring the method of self assembling CPs into self 
assembling monolayers, Motesharei et al. were able to orient cyclic peptides perpendicularly to a 
gold surface and exploit the internal diameter of the CP to show its performance as a size 
selective ion sensor.
[67]
 Using polarised ATR and grazing angle FTIR, Kim et al. found that 
CPNTs were oriented perpendicularly when supported by a lipid matrix, but parallel relative to 
the gold surface in the absence of such a support.
[64]
 Work by Mizrahi et al. used cysteine side 
groups to bind to gold, illustrating the possibility of orientating the CPNTs without a supporting 
matrix. Interestingly the choice of side groups of the CPs (that followed from the initial grafting) 
were chosen such that control over the length of the tube could be achieved by a process 
analogous to layer-by-layer deposition (Scheme 1.3).
[51]
 More recently, Byrne et al. showed the 
use of nanostructured ionic liquids to induce the alignment of cyclic peptide nanotubes.
[97]
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Scheme 1.3: Schematic depiction of the ‘layer-by-layer’-like assembly process. Gold surface was 
successively exposed to solution of cyclo[(-D-Tyr-Lys-D-Tyr-Cys)2] 1, and then to solutions of cyclo[(-D-
Trp-Glu)4] 2 and cyclo[(-D-Tyr-Lys)4] 3, repeatedly, n times (left), resulting in nanotubes containing 2n+1 
self assembled cyclic peptide monomers (right). Blue/red represents positively/negatively charged cyclic 
peptides, respectively. Grey ‘arm’ represents a cysteine side chain. Adapted from Mizrahi et al.[51] 
1.2.7 Applications 
The unique and tuneable nanostructure offered by self assembling CPs prompted their use in 
a range of applications. Most applications of cyclic peptide nanotubes (CPNTs) involve the self 
assembly within lipid bilayers. CPNTs are able to be inserted into lipid bilayers to act as 
channels for the transmembrane transport of ions
[61,64,66,74,98]
 and/or organic molecules
[69,70]
 with 
selectivity which can be tuned by the modification of the ring size (number of residues) or 
introducing charged N-alkylated CPs to act as a gate.
[65,66]
 CPs have also garnered attention as 
antibacterial agents due to their cyclic structure they are proteolytically stable and can assemble 
in bacterial membranes if number and functionality of the residues are appropriately chosen 
(Scheme 1.4).
[59,68]
 Furthermore, to emphasise the elegance of the synthetic approach, a 
combinatorial synthesis allowed the discovery of certain 6 residue CPs to show antibacterial 
properties by screening a library of CPs varying in side chain functionality.
[60]
 Combinatorial 
screening was similarly used to show certain 8 residue CPs had promise as antiviral agents.
[54]
 
Mimicking the environment of lipid membranes self assembled monolayer of organosulfurs on 
gold films were used as a support for the self assembly of CPs, where Motesharei and Ghadiri 
showed the potential for CPs as ion sensors showing selectivity to the ion size with the size of 
the pore.
[67]
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Scheme 1.4: Various modes of membrane permeation where cyclicpeptides are depicted as ring 
structures: (Left to right) Intramolecular pore, barrel stave, and carpet-like. Adapted from Ghadiri et al.
[59]
 
 
Several groups have now exploited self assembling cyclic peptides as a template for 
functional one-dimensional nanostructures by making use of the position of the side chains (i.e. 
at the periphery) of the nanotube. Ghadiri et al. demonstrated with the conjugation of 1,4,5,8-
naphthalenetetracarboxylic acid diimide (NDI) to α-CPs the intermolecular charge transfer 
between dimers
[99]
 and went on to demonstrate delocalised charges when the motif was extended 
to the nanotube assemblies.
[100]
 Several groups have since then covalently attached dyes,
[79,99-102] 
porphyrins,
[103]
 fullerenes (Scheme 1.5),
[104,105]
 ligands and their metal complexes
[106,107]
 to the 
side chains of the cyclic peptides to help elucidate interactions ‘rotational conformers’ between 
two CPs and hetero verse homo dimerisation comparisons but also have applications as ion 
sensors, molecular rotors, light harvesting and nanowires. Dieckmann et al. showed the 
interesting use of CPNTs as a template to selectively solubilise carbon nanotubes by their 
diameter. Linear peptides were designed to have the desired length which would cyclise around 
 
 
Scheme 1.5: Use of self assembling cyclic peptides to template a one-dimensional array of fullerenes. 
Adapted from Granja et al.
[105] 
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the carbon nanotube via the formation of a reversible disulfide bond (incorporated in the 
backbone of peptide to maintain necessary conformation for interannular association).
[108,109]
 By 
covalently linking two N-methylated cyclic peptides separated by an azobenzene linker, Ghadiri 
et al. showed the transition between main-chain supramolecular polymers (intermolecular 
dimerisations) and intramolecular dimerisation with the irradiation of light as a novel route to 
photoresponsive materials.
[110,111]
 The conjugation of polymers to CPs has been a significant 
advance in the use of CP as scaffold for functional nanotubes. This development dramatically 
expands the possibilities in functionality and control to the CP platform which will be discussed 
in the following section (Sub-chapter 1.3). 
1.3 (Cyclic peptide)-polymer conjugates 
The conjugation of synthetic polymers to natural products, particularly biopolymers, is a 
simple and effective approach to combine functionalities which can be engineered for a 
multitude of applications.
[112-114] 
In the last decade self assembling cyclic peptides (CPs) have 
been used as a platform to synthesise polymeric nanotubes. Commonly the CPs are designed to 
drive the supramolecular structure and the tethered polymer serves to introduce a broad range of 
functionality. There are two main synthetic strategies that can be adopted: divergent or 
convergent (Scheme 1.6).
[115] 
Grafting-from is a divergent approach, where one block is synthesised from the other block. 
In most cases using this synthetic route to self assembling (cyclic peptide)-polymer conjugates, 
the polymer block is grown from a pre-synthesised cyclic peptide bearing multiple initiating 
sites. In 2005, Biesalski et al. were the first to produce these hybrid nanotubes by atom-transfer 
radical-polymerisation (ATRP) of N-isopropylacrylamide (NIPAAm) from the alt(D,L)-α-
cyclooctapeptide nanotube scaffold, establishing that the polymer imparted functionality to the 
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Scheme 1.6: Schematically illustrating divergent and convergent synthetic approaches. For example, a 
peptide block with each residue represented as a blue square and a synthetic polymer block with each 
monomer represented as a white circle. 
 
nanotubes, now soluble in common solvents, and with atomic force microscopy (AFM) observed 
the control of the external diameter of the nanotube as a function of polymer conversion.
[116]
 The 
authors then suggest that the repulsive forces between grafted polymer chains could be used to 
tailor the length of the assembly.
[116,117]
 By varying the degree of polymerisation of the attached 
polymer, a general trend was observed by the AFM imaging of the surface absorbed (dry state) 
polymer nanotubes, where it was suggested that the increasing hindrance by the polymer 
shortened the nanotube length.
[118]
 The group of Biesalski have taken advantage of this divergent 
route demonstrating the in-situ crosslinking of the polymer shell by the copolymerisation of 
divinyl monomer,
[119]
 as well as showing the synthetic ease to realise nanotubes with high DP 
polymers.
[120]
 
The alternative approach, grafting prepared polymers onto cyclic peptides, takes a 
convergent route where the blocks are synthesised independently and then coupled together to 
produce the conjugate. This methodology allows researchers to isolate and characterise each 
1 – Introduction 
17 
 
component individually, which is especially appealing in the case of self assembling (cyclic 
peptide)-polymer conjugates which are significantly more difficult to characterise than their 
individual components. By using the same coupling chemistry this approach is also modular, 
allowing a library of components to be set up, which in turn is useful for establishing trends 
across conjugate samples. The convergent approach of conjugating synthetic polymers to CPs 
was first demonstrated in 2006 by Börner et al., attaching two poly(n-butyl acrylate) chains to 
each α-CP using a condensation reaction and show, by AFM, the formation of polymeric 
nanotubes with similar dimensions as those reported by Biesalski et al.
[121] 
Xu and coworkers 
have also taken a convergent approach, showing the pegylation of CPs to make an easily 
processed material. Additionally, CPs were designed to have a methyl group directed towards in 
the internal cavity of the CPNTs, modifying the functionality and reducing cross section of the 
pore.
[63]
 Also significant, the authors demonstrated the utility of conjugating polymers by making 
use of the microphase formation of block copolymers, the self assembly of (cyclic peptide)-
polymer conjugates into the miscible phase resulted with thin films with ordered and oriented 
arrays of sub-nanometer pores (see Figure 1.2), marking an extraordinary opportunity for 
 
 
Figure 1.2: (a) Atomic form microscopy phase image of a ∼32 nm thin film of cyclic peptide-
poly(ethylene oxide) in cylindrical microdomain morphology. (b) Transmission electron microscopy 
image of an in-plane view of a similar thin film. Red circles indicate the cyclic peptide nanotubes aligned 
parallel to the electron beam. Inset shows the zoomed-in image of an in-plane view. Adapted from Xu et 
al.
[122]
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membrane applications.
[122] 
By a different convergent approach, Li et al. modified γ-Ach to 
contain two 3,5-bis(triethylene glycol monomethyl ether)benzoatedendritic ethylene glycol 
chains before carrying out the synthesis of a dipeptide followed by cyclodimerisation to afford 
the cyclotetrapeptide. They reported the observation of nanotubes by AFM and TEM. More 
interestingly, they observed an influence of the degree of lateral aggregation by hydrating the 
dendritic polyethylene oxide side chains prior to deposition.
[83] 
In our group (and in the work presented in this thesis) we have chosen to adopt a convergent 
synthetic approach, since the fundamental nature of our studies requires well-defined conjugates 
to attribute our observations to either the peptide and/or the polymer. We have used reversible 
addition-fragmentation chain transfer (RAFT) polymerisation to synthesise polymers of various 
functionalities and degree of polymerisations, then using copper(I)-catalysed azide-alkyne 
cycloaddition (CuAAC) to conjugate to the cyclic peptide. 
The advent of reversible-deactivation radical polymerisation (RDRP) (also known as living 
or controlled radical polymerisation)
[123]
 has brought about a paradigm shift in polymer 
chemistry allowing for the simple manufacture of narrow molecular weight distributions and 
access to a range of architectures.
[124,125]
 As well as the obvious advantage of having a more 
well-defined structure, we exploit the ‘living’ characteristic behaviour (i.e. polymer chains 
remain dormant by terminating with a reversible end-group), key for us to access end-group 
functionality of the polymer and complementary for conjugation. While there are many RDRP 
techniques available (e.g. nitroxide mediated polymerisation (NMP)
[126]
 and atom transfer radical 
polymerisation (ATRP)
[127]
 are two major alternatives), in this work we use reversible addition-
fragmentation chain transfer (RAFT) polymerisation
[128]
 as it gives access to a wider range of 
monomer functionality and low dispersities when targeting low degree of polymerisations 
compared to other RDRP approaches. We conjugate the peptide and the polymer with 
copper(I)-catalysed azide-alkyne cycloaddition
[129,130]
 as it has the obvious advantage of being an 
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orthogonal reaction, insensitive to the remaining functionalities from the peptide and 
polymer.
[131,132]
 
We have shown the coupling efficiencies when grafting 2-4 polymer chains to α-CPs under a 
range of conditions,
[133,134]
 reporting the difficulty to achieve full conversion of tethering 4 
polymer chains.
[135]
 Benefitting from using RAFT polymerisation, the access to a range of 
monomers allowed the synthesis of pH-
[136]
 and thermo-
[137]
 responsive nanotubes as well as 
stable nanotubes by chemical crosslinks in the polymeric shell.
[138] 
Furthermore, conjugating 
block copolymers allowed the synthesis of hollow nanotubes with tuneable internal and external 
diameters by using a crosslinked polymeric outer-shell and degradable polymeric inner-shell 
(Figure 1.3).
[138]
 Important to the study of these supramolecular systems, CP nanotube 
 
 
Figure 1.3: (Top) Synthetic scheme of crosslinked multishelled nanotubes. (Bottom) Transmission 
electron microscopy images of nanotubes assembled (a) before cross-linking deposited from 
CH2Cl2/CF3COOH (3:1); (b) after cross-linking deposited from tetrahydrofuran and; (c) after ozonolysis 
deposited from tetrahydrofuran. Adapted from Perrier et al.
[138]
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Figure 1.4: Length of (cyclic peptide)-polymer conjugate nanotubes in various solvent mixtures and 
various degree of polymerisations of the polymer side chains, obtained from fitting core-shell-shell 
cylinder model to small angle neutron scattering data. Adapted from Perrier et al.
[139]
 
 
assemblies were characterised in solution by the use of small angle neutron scattering, providing 
evidence of cylindrical assemblies as well as showing the changes in the length of the assembly 
as a function of the tethered polymer DP (Figure 1.4).
[139]
 One notable finding was the ability for 
the polymers to shield the peptide core from the solvent which increases the length of the 
assembly as the polymer DP increases, until ultimately compromised by introduced steric 
repulsion (as observed in the previous reports, albeit in the dry state). 
1.4 Objective 
This work was carried out to address the challenge of engineering nanoscaled objects by 
exploring the potential of controlling self assembly. The self assembly of cyclic peptides is a 
highly versatile platform for the design and synthesis of nanostructures, however the limited 
control of the self assembly hinders wider and improved applications. The recent pairing of 
synthetic polymers with this supramolecular motif has demonstrated its utility by incorporating a 
large range of functionality. While this advancement is beneficial for applications, it also opens 
the use of characterisation techniques that can probe the assembly in solution, leading to the 
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motivation of this research: to tame the self assembly of cyclic peptides and expand the toolbox 
towards accessing more complex nanostructures. 
This study aims to obtain a better understanding of self assembly, examining the large range 
of structures available by varying the components of the system. Conjugates have been 
synthesised to observe the influence on the assembly by grafting polymers, as well as the 
functionality of the peptide and the polymer. The solvating media is also an important 
component of the study to which hydrogen bonding and solvation strengths of a variety of 
solvents and mixtures are studied in relation to the peptides and polymers. Lastly, we endeavour 
to control the lengths of (cyclic peptide)-polymer nanotube assemblies and the functionality of 
the ends of the nanotube assemblies, by exploring bicomponent systems comprising of 
monotopic ((partially N-methylated cyclic peptide)-polymer conjugates) and ditopic species. 
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2 Experimental 
2.1 Peptide synthesis 
Scheme 2.1 shows the general synthetic route for the production of our cyclic peptides. 
 
 
Scheme 2.1: General synthetic overview for the solid phase peptide synthesis and cyclisation. 
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2.1.1 Amino acid modification 
Two modified amino acids were used in this work. Fluorenylmethyloxycarbonyl (Fmoc) 
protected lysine (Fmoc-L-Lys-OH) was modified using a diazotransfer reagent
[140]
 in a method 
described in the literature
[133]
 to give Fmoc-protected azidolysine (Fmoc-L-Lys(N3)-OH) as a 
means to introduce azide functionality, which in turn was utilised as a handle for the conjugation 
of the peptide to the polymer. For the synthesis of monotopic, partially N-methylated cyclic 
peptides (
NMe
CPs), Fmoc-protected N-methylated alanine (Fmoc-N-Me-L-Ala-OH) was prepared 
from Fmoc-N-Me-L-Ala-OH through an oxazolidinone intermediate.
[141]
 
 
Fmoc-L-Lys(N3)-OH 
 
 
Sulfuryl chloride (16.0 mL, 200 mmol) was added dropwise to an ice cold suspension of 
sodium azide (13.0 g, 200 mmol) in acetonitrile (200 mL) and stirred at room temperature 
overnight. The mixture was cooled to 0 °C and imidazole (25.9 g, 380 mmol) was added to the 
mixture over 20 min. The mixture was brought to room temperature where it was stirred for a 
further 3 h. The solution was diluted with EtOAc (400 mL), washed with water (2×400 mL), and 
saturated NaHCO3 (2×400 mL), and then dried over anhydrous magnesium sulfate. A solution of 
hydrochloric acid in ethanol was generated by dropwise addition of acetyl chloride (21.3 mL) to 
EtOH (75 mL, absolute), and added dropwise to the dried EtOAc solution. Upon cooling in an 
ice bath, short colourless needles were collected by filtration and filter cake washed with EtOAc 
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(3×100 mL) yielding imidazole-1-sulfonyl azide hydrochloride: 18.8 g, 54 % yield; mp. 102-
104 °C; IR νmax cm
-1
: 2173, 1429, 1162; 
1
H NMR (300 MHz, D2O) δ ppm: 8.95-9.15 (m, 1H), 
7.89 (m, 1H), 7.47 (m, 1H). 
Fmoc-L-Lys-OH (6.76 g, 18.4 mmol) was ground, dissolved in water (20 mL) then 1 
equivalent of 10 M hydrochloric acid. The solution was diluted with water/methanol (80 mL, 
1:2). Imidazole-1-sulfonyl azide hydrochloride (4.61 g, 22.0 mmol), NaHCO3 (9.95 g, 
0.118 mol), CuSO4·5H2O (0.046 g, 0.18 mmol), was added in turn to the solution and stirred 
overnight at room temperature. MeOH was removed under reduced pressure. The solution was 
diluted with water (200 mL) followed by 5 M hydrochloric acid until the solution reached pH 2. 
The product was extracted, washed with EtOAc, dried with MgSO4, and concentrated in vacuo. 
The product was precipitated into hexane yielding Fmoc-L-Lys(N3) as a white powder: 6.06 g, 
83 % yield; 
1
H NMR (200 MHz, CDCl3) δ ppm: 7.76 (d, J = 7.2 Hz, 2H, 2×fluorenyl-CH), 7.58 
(d, J = 6.6 Hz, 2H, 2×fluorenyl-CH), 7.09-7.48 (m, 4H, 4×aromatic), 4.30-4.66 (m, 3H, Fmoc-
CH2 + α-H), 4.22 (t, J = 6.6 Hz, 1H, Fmoc-CH), 3.04-3.4 (br t, 2H, N3-CH2), 1.1-2.1 (m, 6H, α-
CH2-CH2-CH2); ATR-FTIR νmax cm
-1
: 2092 (N3), 1713 (C=O); HPLC-MS: 17:83 (H2O/CH3CN); 
ESI-LCQ MS, m/z = 417 (M+Na)
+ 
. Data is in good agreement with literature values.
[133]
 
 
Fmoc-N-Me-L-Ala-OH 
 
 
Fmoc-L-Ala-OH (5.00 g, 0.016 mol), paraformaldehyde (3.22 g), p-toluenesulfonic acid 
(0.34 g, 0.0020 mol) in toluene (320 mL) was refluxed overnight at 130 °C in a Dean-Stark 
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setup. Product was washed with saturated NaHCO3 and dried under anhydrous MgSO4. When 
starting material was evident by TLC analysis, the product was passed through a silica plug 
using DCM as the eluent before concentrated to a white solid under vacuum to give (4S)-3-(9-
fluorenylmethyloxycarbonyl)-4-methyl-5-oxo-oxazolidine: 5.01 g, 97 % yield; 
1
H NMR (200 
MHz, DMSO-d6) δ ppm: 7.90 (d, J = 6.8 Hz, 2H, 2×fluorenyl-CH), 7.66 (d, J = 7.0 Hz, 2H, 
2×fluorenyl-CH), 7.26-7.50 (m, 4H, 4×fluorenyl-CH), 4.47 (br d, J = 5.4 Hz, 2H, Fmoc-CH2), 
4.31 (t, J = 5.8 Hz, 1H, Fmoc-CH), 4.09 (q, J = 5.2 Hz, 1H, α-H), 1.18 (br, 3H, α-CH3). 
To a solution of (4S)-3-(9-fluorenylmethyloxycarbonyl)-4-methyl-5-oxo-oxazolidine (5.01 g, 
0.016 mol) and ZnBr2 (7.52 g, 0.033 mol) in dry DCM (310 mL), triethylsilane (5 mL) was 
added and stirred at room temperature under an atmosphere of N2 for 24 h. The crude product 
was diluted with DCM (600 mL), washed with HCl (1 M) and dried over anhydrous MgSO4. 
Recrystallisation from DCM/hexane and washing with cold hexane resulted in long colourless 
crystals of Fmoc-N-Me-L-Ala-OH: 3.91 g, 78 % yield; 
1
H NMR (300 MHz, DMSO-d6) δ ppm: 
12.75 (br s, COOH), 7.90 (d, J = 7.2 Hz, 2H, 2×fluorenyl-CH), 7.65 (m, 2H, 2×fluorenyl-CH), 
7.42 (t, J = 7.2 Hz, 2H, 2×fluorenyl-CH), 7.33 (t, J = 6.9 Hz, 2H, 2×fluorenyl-CH), 4.55 (q, J = 
7.2 Hz, 1H, α-H), 4.21-4.37 (m, 3H, Fmoc-CH + Fmoc-CH2), 2.76 (s, 3H, N-CH3), 1.29 (d, J = 6 
Hz, 3H, α-CH3); 
13
C NMR (75 MHz, CDCl3) δ ppm: 177.5 (COOH), 157.2 (Fmoc-C=O), 144.3 
(fluorenyl-CH), 141.8 (fluorenyl-CH), 128.1 (fluorenyl-CH), 127.5 (fluorenyl-CH), 125.4 
(fluorenyl-CH), 120.5 (fluorenyl-CH), 68.3 (Fmoc-CH2), 54.6 (CHα), 47.6 (Fmoc-CH), 31.0 
(N-CH3), 15.0 (α-CH3); APCI-LCQ MS, m/z = 326 (M+H)
+
; [α]25D = -21° (c = 0.5, DCM); data 
in good agreement with literature.
[142] 
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2.1.2 Solid phase peptide synthesis 
Fmoc solid phase peptide synthesis (SPPS) was used to synthesise the linear octapeptides.
[143-
145] 
 
Linear peptides (LP1 and LP2) 
 
 
 
2-Chlorotrityl chloride resin (1.5 g, 1.5 mmol/g) was transferred to a sintered syringe and 
suspended in DCM, shaken for 30 min and recovered by draining the DCM. A solution of Fmoc-
D-Leu-OH (1.6 g, 4.5 mmol), DIPEA (2.3 g, 18 mmol) in DCM (8 mL) was bubbled with N2 for 
15 min then added to the resin and the suspension shaken for 2 h. The resulting loaded resin was 
washed with a solution of MeOH/DIPEA/DCM (2:1:17, 3×8 mL) then washed with DCM 
(3×8 mL), DMF (3×8 mL), and DCM (3×8 mL). The loaded resin was then dried under vacuum. 
Loading content was determined by deprotecting a sample of the loaded resin (5 mg), by 
agitating in piperidine/DMF (1:4vol, 1 mL, 20 min), then diluted by a factor of 100 with DMF 
and correlating molarity by the absorption of the Fmoc group at λ = 301 nm with 
ε = 7800 M-1cm-1. The loaded resin (0.8 g, 0.65 mmol/g) was transferred to a sintered syringe, 
swollen and agitated in DCM for 30 min. Following the draining of DCM, the resin was washed 
2 – Experimental 
27 
 
with DMF, then the Fmoc groups were removed by the addition of piperidine/DMF (1:4vol, 
2×(8 mL, 5 min)) and agitated. After removing the deprotecting solution, the resin was washed 
with DMF (5×(8 mL, 30 sec)), DCM (5×(8 mL, 30 sec)), and DMF (5×(8 mL, 30 sec)). 
Solutions composed of the Fmoc-amino acid (1.57 mmol), HBTU (1.62 mmol), DIPEA 
(3.1 mmol), DMF (3 mL), bubbled with N2(g), drawn to suspend the resin and agitated for 3 h. 
The addition of azidolysine was an exception where the solutions composed of Fmoc-Lys(N3)-
OH (0.63 mmol), HBTU (0.68 mmol), DIPEA (1.26 mmol), DMF (2 mL), bubbled with N2(g), 
drawn to suspend the resin and agitated overnight. After additions, the resin was washed with 
DMF (5×(8 mL, 30 sec)). Deprotection and addition steps were repeated to obtain the desired 
octapeptide. Following the final addition of amino acid, the peptide chains were deprotected 
once more, washed with DMF (5×(8 mL, 30 sec)), DCM (5×(8 mL, 30 sec)), drained, then 
cleaved from the resin with HFIP/DCM (1:4, 3×(8 mL, 10 min)) and further extracted with DCM 
(3×8 mL). The filtrate was concentrated in vacuo to yield LP as an off-white powder. 
H2N(-L-Lys(N3)-D-Leu-L-Trp(Boc)-D-Leu)2-OH (LP1): 90 % yield; 
1
H NMR (400 MHz, 
TFA-d) δ ppm: 8.12-8.22 (m, 2H, 2×Trp-CHaromatic), 7.29-7.65 (m, 8H, 8×Trp-CHaromatic), 5.14-
5.28 (m, 2H, 2×Trp-α-H), 4.55-4.80 (m, 5H, 4×Leu-α-H + Lys(N3)-α-H), 4.31 (t, J = 6 Hz, 1H, 
Lys(N3)-αNH-H), 3.15-3.45 (m, 8H, 2×Lys(N3)-CH2-N3 + 2×Trp-α-CH2), 0.60-2.18 (br m, 48H, 
2×Lys(N3)-α-CH2-CH2-CH2 + 4×Leu-α-CH2-CH + 8×Leu-CH3); HPLC-MS: UV(230, 
280 nm) = 15:85 (H2O/CH3CN), MS(ESI-LCQ) m/z = 1352 (M+H)
+
. 
H2N(-L-Lys(N3)-D-Leu-L-Lys(Boc)-D-Leu)2-OH (LP2): 96 % yield; 
1
H NMR (400 MHz, 
TFA-d) δ ppm: 4.55-5.00 (m, 7H, 1×Lys(N3)-α-H + 2×Lys-α-H + 4×Leu-α-H), 4.40 (t, J = 6 Hz, 
1H, Lys(N3)-αNH-H), 3.43 (t, J = 6 Hz, 4H, 2×Lys(N3)-CH2-N3), 3.18-3.36 (br m, 4H, Lys-CH2-
NH2), 0.70-2.28 (br m, 60H, 2×Lys(N3)-α-CH2-CH2-CH2 + 2×Lys-α-CH2-CH2-CH2 + 4×Leu-α-
CH2-CH + 8×Leu-CH3). 
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Partially N-methylated linear peptide (
NMe
LP1) 
  
 
2-Chlorotrityl chloride resin (2.0 g, 1.5 mmol/g) was transferred to a sintered syringe and 
suspended in DCM, shaken for 30 min and recovered by draining the DCM. A solution of Fmoc-
D-Phe-OH (2.32 g, 6.0 mmol), DIPEA (3.10 g, 24.0 mmol) in DCM (8 mL) was bubbled with N2 
for 15 min then added to the resin and the suspension shaken for 2 h. The resulting loaded resin 
was washed with a solution of MeOH/DIPEA/DCM (2:1:17, 3×8 mL) then washed with DCM 
(3×8 mL), DMF (3×8 mL), and DCM (3×8 mL). The loaded resin was then dried under vacuum. 
Loading content was determined by deprotecting a sample of the loaded resin (5 mg), by 
agitating in piperidine/DMF (1:4vol, 1 mL, 20 min), then diluted by a factor of 100 with DMF 
and correlating molarity by the absorption of the Fmoc group at λ = 301 nm with 
ε = 7800 M-1cm-1. The loaded resin (0.8 g, 0.73 mmol/g) was transferred to a sintered syringe, 
swollen and agitated in DCM for 30 min. Following the draining of DCM, the resin was washed 
with DMF, then the Fmoc groups were removed by the addition of piperidine/DMF (1:4vol, 
2×(8 mL, 5 min)) and agitated. After removing the deprotecting solution, the resin was washed 
with DMF (5×(8 mL, 30 sec)), DCM (5×(8 mL, 30 sec)), and DMF (5×(8 mL, 30 sec)). 
Solutions composed of the Fmoc-amino acid (0.64 mmol), HBTU (1.17 mmol), DIPEA 
(2.33 mmol), DMF (2.5 mL), bubbled with N2(g), drawn to suspend the resin and agitated 
overnight. In the case of acylation to an N-methylated residue, HATU replaced the use of HBTU 
as the coupling agent in the same molar quantities. After additions, the resin was washed with 
DMF (5×(8 mL, 30 sec)). Deprotection and addition steps were repeated to obtain the desired 
octapeptide. Following the final addition of amino acid, the peptide chains were deprotected 
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once more, washed with DMF (5×(8 mL, 30 sec)), DCM (5×(8 mL, 30 sec)), drained, then 
cleaved from the resin with HFIP/DCM (1:4, 3×(8 mL, 10 min)) and further extracted with DCM 
(3×8 mL). The filtrate was concentrated in vacuo to yield H2N-L-Lys(N3)-D-Phe(-N-Me-L-Ala-D-
Phe)3-OH (
NMe
LP1) as an off-white powder: 530 mg, 89 % yield. 
An alternative synthetic route utilised an automated microwave peptide synthesiser. The 
loaded resin (0.28 g, 0.90 mmol/g) was swollen in DMF for 15 min. For each amino acid 
coupling: the resin was first washed with DMF (7 mL), subjected twice to 20 %vol piperidine 
solution in DMF (7 mL) at 50 °C with 54 W microwave power and washed with DMF (7 mL), 
washed with DMF (4×7 mL), added Fmoc-amino acid in DMF (2.5 mL, 0.12 M), added HBTU 
in DMF (1 mL, 0.5 M), added DIPEA in NMP (1 mL, 2.0 M), left to couple at 50 °C with 27 W 
of microwave power, then washed (3×7 mL). In the case of acylation to an N-methylated residue, 
HATU was added to the Fmoc-amino acid solution and replaced the use of HBTU. Following 
the final addition of amino acid, the peptide chains were deprotected once more, washed with 
DMF (3×7 mL),  DCM (3×7 mL), then cleaved from the resin with HFIP/DCM (1:4, 3×(8 mL, 
10 min)) and further extracted with DCM (3×8 mL). The filtrate was concentrated in vacuo to 
yield H2N-L-Lys(N3)-D-Phe(-N-Me-L-Ala-D-Phe)3-OH (
NMe
LP1) as an off-white powder: 
222 mg, 88 % yield; 
1
H NMR (400 MHz, CDCl3) δ ppm: 7.06-7.04 (br m, 20H, 20×Phe-
CHaromatic), 4.60-5.40 (br m, 7H, + 4×Phe-α-H + 3×N-Me-Ala-α-H), 4.40-4.60 (br m, 1H, 
Lys(N3)-α-H), 2.00-3.40 (br m, 19H, 4×Phe-α-CH2 + 3×N-Me-Ala-N-CH3 + Lys(N3)-CH2-N3), 
0.80-1.85 (br m, 15H, 3×N-Me-Ala-α-CH3 + Lys(N3)-α-CH2-CH2-CH2); 
1
H NMR (300 MHz, 
TFA-d) δ ppm: 6.70-7.65 (br m, 20H, 20×Phe-CHaromatic), 4.75-5.58 (br m, 7H, 4×Phe-α-H + 
3×N-Me-Ala-α-H), 4.15-4.40 (br, 1H, Lys(N3)-α-H), 2.50-3.55 (br m, 19H, 4×Phe-α-CH2 + 3×N-
Me-Ala-N-CH3 + Lys(N3)-CH2-N3), 0.80-2.10 (br m, 15H, 3×N-Me-Ala-α-CH3 + Lys(N3)-
α-CH2-CH2-CH2); HPLC-MS, 34:66 (H2O:CH3CN); ESI-LCQ MS, m/z = 1017 (M+H)
+
. 
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2.1.3 Cyclisation 
Linear peptides were cyclised by head-to-tail coupling under dilute conditions. In 
‘non-N-methylated’ cyclic peptides, 4-(4,6-dimethoxy-1,3,5-triazin)-4-methylmorpholinium 
tetrafluoroborate (DMTMM.BF4) was used as a coupling agent. This coupling agent has been 
chosen as it liberates N-methylmorpholine upon formation of the activated ester intermediate,
[146]
 
removing the need to add additional base and thus minimising racemisation. In the case of the 
N-methylated cyclic peptide, the cheaper (and more common) coupling agent O-(benzotriazol-1-
yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU) was used for cyclisation. Due to 
the lack of an extended structure, analytical and preparative reverse phase high performance 
liquid chromatography (RP-HPLC) could be performed and showed the single elution of 
expected peptide. 
 
4-(4,6-dimethoxy-1,3,5-triazin)-4-methylmorpholinium tetrafluoroborate (DMTMM.BF4) 
 
 
DMTMM.BF4 was prepared by Dr Philip Young, following literature procedures.
[147]
 
N-methylmorpholine (3.50 mL, 37.0 mmol) was added in one portion to a suspension of 2-
chloro-4,6-dimethyl-1,3,5-triazine (6.00 g, 33.6 mmol) in deionised water (100 mL). After 
25 min the solid had dissolved to give a colourless solution to which a solution of NaBF4 (4.42 g, 
40.3 mmol) in deionised water (30 mL) was added dropwise over 20 min. The addition was 
accompanied by crystallisation. The mixture was then left to stir at ambient temperature for a 
further 45 min after which time the solid was collected by vacuum filtration. The precipitate was 
washed sequentially with water (2×25 mL) and MeOH (30 mL) then dried under high vacuum to 
provide DMTMM.BF4 as a colourless crystalline solid: 7.83 g, 71 % yield; 
1
H NMR 
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(300 MHz, DMSO-d6) δ ppm: 4.35 (d, J = 12.14 Hz, 2H, O-CH2-), 4.09 (s, 6H, O-CH3), 4.00 (d, 
J = 12.91 Hz, 2H, O-CH2-), 3.82 (td, J = 22.61, 11.70 Hz, 4H. N-CH2-), 3.46 (s, 2H), 2.08 (s, 2H, 
N-CH3); 
13
C NMR (75 MHz, DMSO-d6) δ ppm: 173.30 (triazine), 73.51 (N-CH2-), 61.30 (O-
CH2-), 59.44 (O-CH3), 56.65 (N-CH3). 
 
Cyclo[(-L-Lys(N3)-D-Leu-L-Trp-D-Leu)2] (CP1) 
 
 
H2N(-L-Lys(N3)-D-Leu-L-Trp(Boc)-D-Leu)2-OH LP1 (0.41 g, 0.31 mmol) was dissolved in 
DMF (20 mL) with 5 min of sonication. The solution was purged with N2(g) at room temperature, 
then cooled with an ice/water bath. DMTMM.BF4 (0.12 g, 0.37 mmol) in DMF (5 mL) was 
purged with N2(g) and added dropwise to the linear peptide solution. The solution was brought to 
room temperature and stirred for 91 h under an atmosphere of N2(g). DMF was removed under 
reduced pressure. The residue was washed with ice/water-cold MeOH (4×20 mL) then dried 
under reduced pressure. Boc groups were removed by treatment with TFA/TIPS/H2O (18:1:1vol, 
5 mL) for 2 h, then triturated with ice/water-cold diethyl ether and washed twice with ice/water-
cold diethyl ether to give CP1 as an off-white powder: 0.25 g, 71 % yield; 
1
H NMR (400 MHz, 
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TFA-d) δ ppm: 8.11 (d, J = 8 Hz, 2H, 2×Trp-CHaromatic), 7.66 (d, J = 8 Hz, 2H, 2×Trp-CHaromatic), 
7.54 (s, 2H, 2×Trp-CHaromatic), 7.26-7.42 (m, 4H, 4×Trp-CHaromatic), 5.21 (t, J = 8 Hz, 2H, 2×Trp-
α-H), 4.60-4.85 (br m, 6H, 4×Leu-α-H + 2×Lys(N3)-α-H), 3.00-3.40 (br m, 8H, 2×Lys(N3)-CH2-
N3 + 2×Trp-α-CH2), 0.50-2.00 (br m, 48H, 2×Lys(N3)-α-CH2-CH2-CH2 + 4×Leu-α-CH2-CH + 
8×Leu-CH3); MALDI-FTICR MS m/z = 1155.67 (M+Na)
+
; ATR-FTIR νmax cm
-1
: 3270 (N-Hstr), 
2093 (N3), 1626 (C=Ostr). 
 
Cyclo[(-L-Lys(N3)-D-Leu-L-Lys(Boc)-D-Leu)2] (CP2) 
 
 
H2N(-L-Lys(N3)-D-Leu-L-Lys(Boc)-D-Leu)2-OH LP2 (0.09 g, 0.08 mmol) was dissolved in 
DMF (73 mL) with 1 h of sonication at 40 °C. The solution was purged with N2(g). 
DMTMM.BF4 (0.03 g, 0.09 mmol) in DMF (3 mL) was purged with N2(g) and added dropwise to 
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the linear peptide solution. The solution was stirred for 67 h at 40 °C under an atmosphere of 
N2(g). DMF was removed under reduced pressure. The residue was washed with dry-ice/acetone-
cold MeOH (2×10 mL) then dried under reduced pressure to give CP2 as a white powder: 
42 mg, 45 % yield; 
1
H NMR (400 MHz, TFA-d); 
1
H NMR (400 MHz, TFA-d) δ ppm: 4.60-5.00 
(m, 8H, 2×Lys(N3)-α-H + 2×Lys-α-H + 4×Leu-α-H), 3.41 (t, J = 6 Hz, 4H, 2×Lys(N3)-CH2-N3), 
3.20-3.34 (br m, 4H, Lys-CH2-NH2), 1.25-2.12 (br m, 36H, 2×Lys(N3)-α-CH2-CH2-CH2 + 
2×Lys-α-CH2-CH2-CH2 + 4×Leu-α-CH2-CH), 0.91-1.11 (br m, J = 8 Hz, 24H, 8×Leu-CH3); 
ESI-LCQ MS m/z = 1240 (M+Na)
+
; ATR-FTIR νmax cm
-1
: 3270 (N-Hstr), 3037-2800 (C-Hstr), 
2096 (N3), 1624 (C=Ostr). 
 
Cyclo[(-L-Lys(N3)-D-Leu-L-Lys-D-Leu)2] (CP3) 
 
 
H2N(-L-Lys(N3)-D-Leu-L-Lys(Boc)-D-Leu)2-OH LP2 (0.19 g, 0.15 mmol) was dissolved in 
DMF (142 mL) with 75 min of sonication at 40 °C. The solution was purged with N2(g). 
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DMTMM.BF4 (0.06 g, 0.18 mmol) in DMF (20 mL) was purged with N2(g) and added dropwise 
to the linear peptide solution. The solution was stirred for 67 h at 40 °C under an atmosphere of 
N2(g). DMF was removed under reduced pressure. Boc groups were removed by treatment with 
TFA/thioanisole/TIPS/H2O (88:5:2:5vol, 20 mL) for 2 h, then washed with ice/acetone-cold 
acetic acid/diethyl ether (1:1vol, 2×40 mL), washed twice with dry-ice/acetone-cold diethyl ether 
(2×40 mL) and then dried under reduced pressure to give CP3 as a white powder: 63 mg, 33 % 
yield; 
1
H NMR (400 MHz, TFA-d) δ ppm: 4.75-5.15 (m, 8H, 2×Lys(N3)-α-H + 2×Lys-α-H + 
4×Leu-α-H), 3.56 (t, J = 8 Hz, 4H, 2×Lys(N3)-CH2-N3), 3.33-3.50 (br m, 4H, Lys-CH2-NH2), 
1.40-2.26 (br m, 36H, 2×Lys(N3)-α-CH2-CH2-CH2 + 2×Lys-α-CH2-CH2-CH2 + 4×Leu-α-CH2-
CH), 1.17 (d, J = 8 Hz, 24H, 8×Leu-CH3); MALDI-FTICR MS m/z = 1068 (M-2N2+Ag)
+
; ATR-
FTIR νmax cm
-1
: 3273 (N-Hstr), 3006-2790 (C-Hstr), 2099 (N3), 1627 (C=Ostr). 
 
Cyclo[-L-Lys(N3)-D-Phe(-N-Me-L-Ala-D-Phe)3] (
NMe
CP1) 
 
 
H2N-L-Lys(N3)-D-Phe(-N-Me-L-Ala-D-Phe)3-OH 
NMe
LP1 (0.30 g, 0.30 mmol) was dissolved 
in DMF (200 mL) and purged with N2 while cooled in an ice bath. HBTU (0.17 g, 0.44 mmol), 
HOBt (0.060 g, 0.44 mmol), DIPEA (0.12 g, 0.90 mmol) was separately mixed with DMF 
(25 mL total) and sequentially added dropwise to the linear peptide solution. The solution was 
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brought to room temperature and stirred for 48 h under an atmosphere of N2. The crude product 
was concentrated under vacuum, redissolved in acetonitrile and purified by preparative RP-
HPLC (60:40 to 0:100 (water:acetonitrile [0.01 % TFA]) over 60 min, 7 mL/min, tR = 48 min) to 
obtain cyclo[-L-Lys(N3)-D-Phe-(N-Me-L-Ala-D-Phe-)3] 
NMe
CP1 as a white powder: 96.0 mg, 
33 % yield; 
1
H NMR (300 MHz, CDCl3) δ ppm: 8.34-8.86 (br m, NHdimer), 7.05-7.38 (br m, 20H, 
20×Phe-CHaromatic), 6.40-6.71 (br m, NHunimer), 4.50-5.93 (br m, 8H, Lys(N3)-α-H + 4×Phe-α-H + 
3×N-Me-Ala-α-H), 2.60-3.30 (br m, 19H, 4×Phe-α-CH2 + 3×N-Me-Ala-N-CH3 + 
Lys(N3)-CH2-N3), 0.35-1.55 (br m, 15H, 3×N-Me-Ala-α-CH3 + Lys(N3)-α-CH2-CH2-CH2); 
1
H NMR (300 MHz, THF-d8) δ ppm: 8.30-8.90 (br m, NHdimer), 7.65-7.85 (br, NHLys), 7.02-7.38 
(br m, 20H, 20×Phe-CHaromatic), 4.20-6.00 (br m, NHunimer + 8H, NHunimer + Lys(N3)-α-H + 
4×Phe-α-H + 3×N-Me-Ala-α-H), 2.55-3.30 (br m, 19H, 4×Phe-α-CH2 + 3×N-Me-Ala-N-CH3 + 
Lys(N3)-CH2-N3), 0.60-1.45 (br m, 15H, 3×N-Me-Ala-α-CH3 + Lys(N3)-α-CH2-CH2-CH2); 
1
H NMR (300 MHz, THF-d8 + LiBr (1:9 ([2]:[LiBr])) δ ppm: 9.71 (d, J = 9 Hz, 1H, NHPhe), 9.58 
(d, J = 9 Hz, 1H, NHPhe), 9.51 (d, J = 9 Hz, 1H, NHPhe), 9.11 (d, J = 6 Hz, 1H, NHLys), 8.79 (d, 
J = 6 Hz, 1H, NHPhe), 7.71 (d, J = 6 Hz, 2H, 2×Phe-α-CHaromatic), 6.95-7.50 (m, 18H, 18×Phe-
α-CHaromatic), 5.53 (q, J = 7 Hz, 1H, N-Me-Ala-α-H), 4.72-5.42 (m, 7H, Lys(N3)-α-H + 4×Phe-α-
H + 2×N-Me-Ala-α-H), 3.10-3.50 (br m, 8H, Lys(N3)-CH2-N3 + 3×Phe-α-CH2), 2.75-2.92 (br m, 
2H, Phe-α-CH2), 2.40-2.65 (br m, 9H, 3×N-Me-Ala-N-CH3), 0.80-1.60 (br m, 15H, Lys(N3)-
α-CH2-CH2-CH2 + 3×N-Me-Ala-α-CH3); HPLC-MS: 10:90 (H2O:CH3CN) ; ESI-LCQ MS, m/z = 
999 (M+H)
+
, 1021 (M+Na)
+
; ATR-FTIR νmax cm
-1
: 3300 (N-Hstr), 3120-2830 (C-Hstr), 1622 
(C=Ostr), 2095 (N3). 
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2.2 Polymer synthesis 
In RAFT polymerisation, the end-groups of the polymer are determined by the RAFT agent 
used, which is modified pre-polymerisation to introduce alkyne functional groups, used for 
conjugation. Scheme 2.2 shows the general synthetic route for the production of our polymers. 
 
 
Scheme 2.2: General synthetic overview for RAFT agent modification and RAFT polymerisation. 
 
2.2.1 RAFT agent modification 
r-functional alkyne RAFT agent (PPBTC) 
 
 
(Propynyl 2-propanoate)yl butyl trithiocarbonate (PPBTC) was prepared following a similar 
protocol from our group.
[148]
 2-Propanoic acid butyl trithiocarbonate (PABTC, 1.03 g, 
4.30 mmol) was dissolved in DCM (50 mL) and cooled in an ice bath. Propargyl alcohol (1.21 g, 
21.51 mmol), DMAP (0.54 g, 4.42 mmol) and EDCI (1.65 g, 8.61 mmol) was added to the 
solution. The reaction was left to stir for 2 h at 0 °C then for a further 16 h at room temperature. 
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The solution was washed with water (5×20 mL), dried with anhydrous MgSO4, concentrated and 
passed over a silica pad with toluene/EtOAc (9:1). The product was concentrated under vacuum 
to yield PPBTC as a yellow oil: 1.08 g, 72 % yield; 
1
H NMR (300 MHz, CDCl3) δ ppm: 4.85 (q, 
J = 8 Hz, 1H, R-CH-COO), 4.73 (m, 2H, COO-CH2), 3.37 (t, J = 7.5 Hz,  2H, Z-CH2), 2.50 (t, J 
= 3 Hz, 1H, R-C≡CH), 1.54-1.76 (m, 5H, R-CH3 + Z-CH2), 1.44 (sext., J = 7.2 Hz, 2H, Z-CH2), 
0.94 (t, J = 7.5 Hz, 3H, Z-CH3). 
 
z,r-functional dialkyne RAFT agent (PPPPTC) 
 
 
2-Propanoic acid 3-propanoic acid trithiocarbonate (PAPATC, 1.00 g, 3.93 mmol), propargyl 
alcohol (0.98 g, 0.018 mol) and DMAP (0.145 g, 1.19 mmol) was dissolved in DCM (5 mL) and 
cooled to -20 °C. EDCI (2.69 g, 0.0140 mol) was suspended in DCM (20 mL), cooled to -20 °C 
and then added dropwise to the main solution. The reaction was left to stir for 20 h at room 
temperature. The resulting solution was diluted with DCM, washed with HCl (1 M, 70 mL), 
NaOH (1 M, 70 mL) and water (70 mL), dried with anhydrous MgSO4, concentrated and 
purified over a silica column with DCM as the eluent. The product was concentrated under 
vacuum to yield (propynyl 2-propanoate)yl (propynyl 3-propanoate)yl trithiocarbonate 
(PPPPTC) as a yellow oil: 0.595 g, 46 % yield; 
1
H NMR (300 MHz, CDCl3) δ ppm: 4.83 (q, J = 
7.4 Hz, 1H, R-CH-COO), 4.68-4.77 (m, 4H, Z-COO-CH2 + R-COO-CH2), 3.63 (t, J = 6.9 Hz, 
2H, Z-S-CH2), 2.82 (t, J = 6.9 Hz, 2H, Z-CH2-COO), 2.51 (dt, J = 3.6, 2.6 Hz, 2H, Z-C≡CH + R-
C≡CH), 1.62 (d, J = 7.2 Hz, 3H, R-CH3); ESI-LCQ MS, m/z = 353 (M+Na)
+
. 
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2.2.2 RAFT polymerisation 
α-alkyne polymers (pBA16-alkyne, pBA30-alkyne, p(BA-d9)29-alkyne, and pSty20-alkyne) 
 
 
Polymers with an alkyne end-group were synthesised by RAFT polymerisation. 
PBA16-alkyne, pBA30-alkyne, and p(BA-d9)29-alkyne were synthesised by Robert Chapman. 
PPBTC (0.25 g, 0.9 mmol), BA (2.0 g, 16.2 mmol) and AIBN (0.015 g, 0.09 mmol) was mixed 
and diluted to 40 % (w/w) with dioxane, cooled in an ice bath and purged with N2 for 15 min 
before stirring at 70 °C under an atmosphere of N2 until 79 % conversion determined by 
1
H NMR. The polymer was precipitated and washed with ice-cold water/MeOH (1:9) to yield 
pBA16-alkyne as a yellow viscous liquid: Mn (
1
H NMR) = 2300 g·mol
-1
; 
1
H NMR (200 MHz, 
CDCl3) δ ppm: 4.72-4.90 (br m, 1H, pBA-S-CH), 4.60-4.70 (br m, 2H, PPBTCR-COO-CH2), 
3.85-4.24 (br m, 32H, pBA-COO-CH2), 3.51 (t, J = 7.3 Hz, 2H, S-CH2), 0.50-2.51 (br m, 171H,  
PPBTCZ-CH2-CH2-CH3 + 16×p(BA)-CH2-CH2-CH3 + 16×pBAbackbone-CH-CH2 + PPBTCR-CH3 
+ PPBTCR-C≡CH); SEC-DRI(DMF+LiBr): Mn = 2300 g·mol
-1
, Đ = 1.15. MALDI-FTICR MS: 
(M+Na)
+
 observed; repeat unit m/z = 128, end-group m/z = 276. 
In the same manner, pBA30-alkyne and p(BA-d9)29-alkyne was synthesised using 
[BA]:[PPBTC] of 35:1 and was halted at 79 % conversion (
1
H NMR): Mn (
1
H NMR) = 
4200 g·mol
-1
; 
1
H NMR (400 MHz, CDCl3) δ ppm: 4.78-4.88 (m, 1H, pBA-S-CH), 4.58-4.72 (m, 
2H, PPBTCR-COO-CH2), 3.80-4.30 (m, 30×2H, pBA-COO-CH2), 3.34 (t, J = 6 Hz, 2H, S-CH2), 
0.70-2.60 (m, 311H,  PPBTCZ-CH2-CH2-CH3 + 30×pBA-CH2-CH2-CH3 + 30×pBAbackbone-CH-
CH2 + PPBTCR-CH3 + PPBTCR-C≡CH); SEC-DRI(DMF+LiBr): Mn = 3500 g·mol
-1
, Đ = 1.16. 
MALDI-ToF MS: (M+Na)
+
 observed; repeat unit m/z = 128, end-group m/z = 276. 
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PSty20-alkyne was synthesised by RAFT polymerisation. PPBTC (0.21 g, 0.76 mmol), 
styrene (3.03 g, 29.0 mmol) and AIBN (0.012 g, 0.073 mmol) was mixed and cooled in an ice 
bath while bubbled with N2 for 10 min before stirring for 65 °C under atmosphere of N2 until 
50 % conversion. The crude product was dissolved in DCM, precipitated and washed with ice 
cold MeOH. Purification was repeated twice more to yield pSty20-alkyne as a solid yellow 
powder: Mn (SEC-DRI) = 2400 g·mol
-1
, Đ = 1.15; 1H NMR (200 MHz, CDCl3) δ ppm: 7.35-6.25 
(br m, 100H, 20×5×CHaromatic), 5.10-4.15 (br m, 3H, pSty-S-CH + PPBTCR-COO-CH2), 3.15-
3.35 (br m, 2H, PPBTCz-S-CH2), 2.50-0.65 (br m, 71H, PPBTCR-C≡CH + 20×pStybackbone-CH-
CH2 + PPBTCR-CH3 + PPBTCZ-CH2-CH2-CH3). MALDI-FTICR MS: (M+Na)
+
 
observed; repeat unit m/z = 104, end-group m/z = 276. 
 
α,ω-dialkyne polymer (pBA22-dialkyne) 
 
 
Poly(butyl acrylate) with an alkyne functionality at each end-group pBA22-dialkyne was 
synthesised by RAFT polymerisation. PPPPTC (0.071 g, 0.22 mmol), AIBN (0.0038 g, 
0.023 mmol) and BA (1.00 g, 7.80 mmol) in dioxane (2 mL) was cooled in a cold water bath and 
purged with N2 for 20 min. The reaction was stirred at 70 °C under an atmosphere of N2 until 66 
% conversion determined by 
1
H NMR. The polymer was precipitated and washed with ice-cold 
water/MeOH (1:9) until 
1
H NMR analysis showed no vinyl peaks due to BA monomer. 
PBA22-dialkyne was obtained as a yellow viscous liquid: Mn (
1
H NMR) = 3200 g·mol
-1
; 
1
H NMR (300 MHz, CDCl3) δ ppm: 4.62-4.88 (br m, 5H, PPPPTCR-COO-CH2 + PPPPTCZ-
COO-CH2 + pBA-S-CH), 3.86-4.22 (br m, 44H, 22×pBA-COO-CH2), 3.62 (br t, J = 6.9 Hz, 2H, 
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PPPPTCZ-S-CH2), 2.81 (br t, J = 6.9 Hz, 2H, PPPPTCZ-CH2-COO), 1.06-2.61 (br m, 160H, 
PPPPTCR-CH-CH3 + 22×pBA-CH2-CH2 + 22×pBAbackbone-CH-CH2 + PPPPTCZ-C≡CH + 
PPPPTCR-C≡CH), 0.94 (t, J = 7.4 Hz, 66H, 22×pBA-CH3); SEC-DRI(DMF+LiBr): 
Mn = 3200 g·mol
-1
, Đ = 1.14; ESI-FTICR and MALDI-ToF MS: (M+Na)+ observed; repeat unit 
m/z = 128, end-group m/z = 330. 
2.3 Peptide-polymer conjugation 
We covalently grafted peptides and polymers by microwave assisted CuAAC using a method 
by Rijkers et al. as a basis for the reaction.
[149]
 Protocols have been developed by our group 
demonstrating that the efficiency of this reaction requires only a slight excess of polymer (to 
account for any chain termination during polymerisation) to yield full conversion in coupling 2 
polymers per peptide, ensuring the product is not a combination of 0-2 armed conjugates and 
removing the need purify excess polymer.
[135]
 A range of conjugates were synthesised (Scheme 
2.3, 2.4, and 2.5) 
2.3.1 CP-based conjugates 
CP1-(pBA30)2 and CP1-(p(BA-d9)29)2 
CP1-(pBA30)2 and CP1-(p(BA-d9)29)2 was synthesised following a protocol from our 
group.
[135]
 CP1 (40 mg, 0.035 mmol) was suspended in TFE (2 mL) by sonication for 10 min. 
PBA30-alkyne (0.31 g, 0.074 mmol), sodium ascorbate (0.14 g, 0.71 mmol), copper(II) sulphate 
pentahydrate (0.037 g, 0.14 mmol) in DMF (3 mL) was added to the cyclic peptide solution, 
placed in a microwave reactor, irradiated (dynamic mode) at 100 °C for 15 min with a flow of 
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Scheme 2.3: Synthetic overview of ditopic (cyclic peptide)-polymer conjugates. 
 
N2(g) and delivering 200 W in the initial ramp. TFE and DMF was removed under reduced 
pressure. The crude product was dissolved in DCM and washed with EDTA (2×30 mL, 0.055 M, 
pH 8.5), washed with water (30 mL), and dried over MgSO4. Concentrated in vacuo, CP1-
(pBA30)2 was obtained as a brown film: 145 mg; 
1
H NMR (300 MHz, TFA-d) δ ppm: 8.48 (s, 
2H, 2×triazole-CH), 7.60 (s, 2H, 2×Trp-CHaromatic), 7.34 (s, 2H, 2×Trp-CHaromatic), 7.02-7.26 (m, 
6H, 6×Trp-CHaromatic), 5.46 (s, 4H, 2×O-CH2-triazole), 5.18 (s, 2H, 2×Trp-α-H), 4.52-4.87 (m, 
6H, 4×Leu-α-H + 2×Lys-α-H), 4.24 (s, 64H, 32×pBA-O-CH2), 3.95 (s, 2H, PPBTCz-CH2), 1.71 
(s, 64H, 32×pBA- CH2), 1.42 (s, 64H, 32×pBA-CH2), 0.98 (s, 96H, 32×pBA-CH3), 0.73-0.89 
(m, 24H, 8×Leu-CH3), 0.45 (d, J = 10.15 Hz, 3H, PPBTCr-CH3), 0.22-0.15 (m, 3H, PPBTCz-
CH3); ATR-FTIR νmax cm
-1
: 3274 (N-Hstr), 3045-2750 (C-Hstr), 1728 (C=Op(BA)), 1625 (C=OCP-
str). 
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CP2-(pBA30)2 
CP2 (10 mg, 0.008 mmol), pBA30-alkyne (0.071 g, 0.017 mmol), sodium ascorbate (0.016 g, 
0.081 mmol), copper(II) sulphate pentahydrate (0.009 g, 0.036 mmol) was suspended in DMF 
(3 mL), placed in a microwave reactor, irradiated (dynamic mode) at 100 °C for 15 min with a 
flow of N2(g) and delivering 200 W in the initial ramp. DMF was removed under reduced 
pressure. In attempting to push the reaction to completion, a second microwave irradiation was 
performed after adding sodium ascorbate (0.016 g, 0.081 mmol), CuSO4.5H2O (0.009 g, 
0.036 mmol) in DMF (3 mL). The crude product was dissolved in CHCl3 and washed with 
EDTA (2×30 mL, 0.055 M, pH 8.5), washed with water (30 mL), and dried over MgSO4. 
Concentrated in vacuo, CP2-(pBA30)2 was obtained as a dark brown film: 54 mg; ATR-FTIR 
νmax cm
-1
: 3272 (N-Hstr), 3040-2800 (C-Hstr), 2098 (N3), 1729 (C=Op(BA)), 1624 (C=OCP-str). 
 
CP2-(pBA30)1.5 
CP2 (5 mg, 0.004 mmol), pBA30-alkyne (0.024 g, 0.006 mmol), sodium ascorbate (0.008 g, 
0.040 mmol), copper(II) sulphate pentahydrate (0.005 g, 0.020 mmol) was suspended in DMF 
(2.5 mL), placed in a microwave reactor, irradiated (dynamic mode) at 100 °C for 15 min with a 
flow of N2(g) and delivering 200 W in the initial ramp. DMF was removed under reduced 
pressure. The crude product was dissolved in CHCl3 and washed with EDTA (2×30 mL, 
0.055 M, pH 8.5), washed with water (30 mL), and dried over MgSO4. Concentrated in vacuo, 
CP2-(pBA30)1.5 was obtained as a brown film: 20 mg; ATR-FTIR νmax cm
-1
: 3270 (N-Hstr), 3040-
2800 (C-Hstr), 2097 (N3), 1732 (C=Op(BA)), 1625 (C=OCP-str). 
 
CP3-(pBA30)2 
CP3 (10 mg, 0.008 mmol), pBA30-alkyne (0.085 g, 0.021 mmol), sodium ascorbate (0.020 g, 
0.098 mmol), copper(II) sulphate pentahydrate (0.010 g, 0.039 mmol) was suspended in DMF 
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(2 mL), placed in a microwave reactor, irradiated (dynamic mode) at 100 °C for 15 min with a 
flow of N2(g) and delivering 200 W in the initial ramp. DMF was removed under reduced 
pressure. The crude product was dissolved in DCM and washed with EDTA (2×30 mL, 0.055 M, 
pH 8.5), washed with water (30 mL), and dried over MgSO4. Concentrated in vacuo, CP2-
(pBA30)2 was obtained as a dark brown film: 52 mg; ATR-FTIR νmax cm
-1
: 3279 (N-Hstr), 3050-
2800 (C-Hstr), 1733 (C=Op(BA)), 1631 (C=OCP-str). 
 
CP3-(pBA30)1.5 
CP3 (10 mg, 0.008 mmol), pBA30-alkyne (0.062 g, 0.015 mmol), sodium ascorbate (0.021 g, 
0.11 mmol), copper(II) sulphate pentahydrate (0.011 g, 0.042 mmol) was suspended in DMF 
(2 mL), placed in a microwave reactor, irradiated (dynamic mode) at 100 °C for 15 min with a 
flow of N2(g) and delivering 200 W in the initial ramp. DMF was removed under reduced 
pressure. The crude product was dissolved in DCM and washed with EDTA (2×30 mL, 0.055 M, 
pH 8.5), washed with water (30 mL), and dried over MgSO4. Concentrated in vacuo, CP2-
(pBA30)2 was obtained as a dark brown film: 49 mg; ATR-FTIR νmax cm
-1
: 3280 (N-Hstr), 3060-
2800 (C-Hstr), 1733 (C=Op(BA)), 1631 (C=OCP-str). 
2.3.2 NMeCP-based conjugates 
Monotopic conjugates (
NMe
CP1-pBA16, 
NMe
CP1-pBA30, 
NMe
CP1-pSty20) 
NMe
CP1 (0.015 g, 0.015 mmol), alkyne functionalised polymer pBA16-alkyne, pBA30-alkyne 
or pSty20-alkyne (0.0165 mmol), copper(II) sulphate pentahydrate (0.008 g, 0.03 mmol), sodium 
ascorbate (0.06 g, 0.3 mmol) and DMF (2 mL) were transferred to a microwave vial and mixed. 
The reaction mixture was placed in a microwave reactor, stirred and irradiated (dynamic mode) 
at 100 °C for 15 min with a flow of N2 and delivering 200 W in the initial ramp. DMF was 
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Scheme 2.4: Synthetic overview of monotopic (N-methylated cyclic peptides)-polymer conjugates. 
 
removed under reduced pressure. The crude product was diluted with DCM, washed with EDTA 
(2×30 mL, 0.055 M, pH 8.5), washed with water (30 mL), and dried over MgSO4. Concentrated 
in vacuo, 
NMe
CP1-pBA16 and 
NMe
CP1-pBA30 was obtained as a brown film. Concentrated in 
vacuo with MeOH, afforded 
NMe
CP1-pSty20 as a white and brown powder. See product after 
copper removal for characterisations. 
NMe
CP1-pBA16 used for the ATR-FTIR and SEC studies in Sub-chapter 4.3 was synthesised 
and purified by an alternative route: 
NMe
CP1 (0.010 g, 0.010 mmol), pBA16-alkyne (0.036 g, 
0.016 mmol, Mn = 2300 g·mol
-1
, Đ = 1.15), copper(II) sulphate pentahydrate (0.0050 g, 
0.020 mmol), sodium ascorbate (0.041 g, 0.21 mmol) and DMF (2 mL) were transferred to a 
microwave vial and subjected to the same microwave conditions as above. DMF was removed 
under reduced pressure. To remove copper and excess unconjugated polymer, the product was 
dissolved in acetonitrile and loaded onto a column of neutral alumina. Elution with acetonitrile, 
followed by methanol gave the conjugate 
NMe
CP1-pBA16, after concentration of the appropriate 
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fractions under vacuum, as a film of yellow liquid: 9.7 mg, 31 % yield; 
1
H NMR (300 MHz, 
CDCl3) δ ppm: 8.35-8.80 (br m, NHdimer), 7.50-7.60 (br m, 1H, triazole-CH), 7.05-7.40 (br m, 
20×Phe-CH), 6.32-7.05 (br m, NHunimer), 4.45-6.00 (br m, 11H, 3×Ala-α-H + 4×Phe-α-H + Lys-
α-H + pBA-S-CH + PPBTCR-O-CH2), 3.65-4.35 (br m, 34H, 16×pBA-O-CH2 + triazole-N-CH2), 
3.35 (t, J = 7.4 Hz, 2H, S-CH2), 2.66-3.28 (br m, 17H, 4×Phe-CH2 + 3×Ala-N-CH3), 0.20-2.60 
(br m, 185H, 16×p(BA)-CH2-CH2-CH3 + 16×pBAbackbone-CH-CH2 + PPBTCZ-CH2-CH2-CH3 + 
PPBTCR-CH3 + 3×Ala-α-CH3 + Lys-α-CH2-CH2-CH2); ATR-FTIR νmax cm
-1
: 3304 (N-Hstr), 
3100-2810 (C-Hstr), disappearance of 2095 (N3), 1732 (C=Op(BA)), 1628 (C=OCP-str). 
 
 
Scheme 2.5: Synthetic overview of ditopic (N-methylated cyclic peptides)-polymer conjugate. 
 
Ditopic conjugate (di
NMe
CP-pBA22) 
Microwave assisted copper(I)-catalysed azide-alkyne cycloaddition was used to graft the 
polymer to the cyclic peptide under conditions similar to the synthesis of 
NMe
CP1-pBA16, 
NMe
CP1-pBA30 and 
NMe
CP1-pSty20. PBA22-dialkyne (0.030 g, 0.0094 mmol, 
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Mn = 3200 g·mol
-1
, Đ = 1.14), NMeCP1 (0.021 g, 0.021 mmol), copper(II) sulphate pentahydrate 
(0.0094 g, 0.038 mmol), sodium ascorbate (0.074 g, 0.38 mmol) and DMF (2 mL) were 
transferred to a microwave vial. The reaction mixture was then placed in a microwave reactor, 
stirred and irradiated at 100 °C for 15 min with a flow of N2 and delivering 200 W in the initial 
ramp. DMF was removed under vacuum and the product was redissolved in DCM, washed with 
EDTA (3x30 mL, 0.055 M, pH 8.5) and water (2x50 mL). Dried with anhydrous MgSO4 and 
concentrated under vacuum, (cyclic peptide)-polymer conjugate di
NMe
CP-pBA22 was obtained as 
a brown oil: 32.3 mg, 66 % yield; 
1
H NMR (200 MHz, CDCl3) δ ppm: 8.30-8.85 (br m, NHdimer), 
7.05-7.80 (br m, 42H, 40×Phe-CH + 2×triazole-CH), 6.65-6.85 (br m, NHunimer), 4.45-6.00 (br m, 
21H, 6×Ala-α-H + 8×Phe-α-H + 2×Lys-α-H + pBA-S-CH + 2×PPPPTC-O-CH2-triazole), 3.60-
4.45 (br m, 48H, 22×pBA-O-CH2 + 2×Lys-CH2-triazole), 2.60-3.60 (br m, 38H, 8×Phe-CH2 + 
6×Ala-N-CH3 + PPPPTCz-S-CH2-CH2), 0.20-2.60 (br m, 254H, 22×pBA-CH2-CH2-CH3 + 
22×pBAbackbone-CH-CH2 + PPPPTCR-CH-CH3 + 6×Ala-α-CH3 + 2×Lys-α-CH2-CH2-CH2); ATR-
FTIR νmax cm
-1
: 3304 (N-Hstr), 3050-2810 (C-Hstr), disappearance of 2095 (N3), 1728 (C=Op(BA)), 
1630 (C=OCP-str). 
 
Removal of copper nanoparticles (I2 treatment) 
As written in the above synthesis of 
NMe
CP-pBA16, 
NMe
CP-pBA16 was used in some studies 
after being passed over a column of neutral alumina to remove copper as well as excess polymer. 
An alternative treatment that was used to remove copper is shown below. 
The crude product of conjugate 
NMe
CP-pBA16 (20 mg) in DCM (2.0 mL) was added to I2 
(0.083 g) and stirred for 18 h. The mixture was diluted with DCM and washed with an aqueous 
solution containing EDTA (0.055 M) and sodium thiosulfate pentahydrate (0.053 M) (2×30 mL, 
pH 8.5) followed by water (30 mL). The resulting yellow solution was dried with MgSO4 and 
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concentrated under vacuum. Affording 
NMe
CP-pBA16 as a yellow light-brown film: 15 mg;
 
1
H NMR (200 MHz, CDCl3) δ ppm: 8.35-8.80 (br m, NHdimer), 7.49-7.62 (br, 1H, triazole-CH), 
7.05-7.45 (br m, 20×Phe-CH), 6.35-6.70 (br m, NHunimer), 4.45-6.00 (br m, 11H, 3×Ala-α-H + 
4×Phe-α-H + Lys-α-H + pBA-S-CH + PPBTCR-O-CH2), 3.75-4.35 (br m, 36H, 16×pBA-O-CH2 
+ Lys-CH2-triazole), 3.27-3.45 (br, 2H, S-CH2), 2.66-3.27 (br m, 17H, 4×Phe-CH2 + 3×Ala-N-
CH3), 0.20-2.60 (br m, 185H, 16×pBA-CH2-CH2-CH3 + 16×pBAbackbone-CH-CH2 + PPBTCZ-
CH2-CH2-CH3 + PPBTCR-CH3 + 3×Ala-α-CH3 + Lys-α-CH2-CH2-CH2); ATR-FTIR νmax cm
-1
: 
3305 (N-Hstr), 3120-2800 (C-Hstr), disappearance of 2095 (N3), 1733 (C=Op(BA)), 1628 (C=OCP-
str). Mp (SEC-DRI(THF)) = 5000 g·mol
-1
. 
The crude product of conjugate 
NMe
CP-pBA30 (17 mg) in DCM (2.0 mL) was added to I2 
(0.034 g) and stirred for 18 h. The mixture was diluted with DCM and washed with an aqueous 
solution containing EDTA (0.055 M) and sodium thiosulfate pentahydrate (0.053 M) (2×30 mL, 
pH 8.5) followed by water (30 mL). The resulting yellow solution was dried with MgSO4 and 
concentrated under vacuum. Affording 
NMe
CP-pBA30 as a yellow light-brown film: 15 mg; 
1
H NMR (200 MHz, CDCl3) δ ppm: 8.35-8.85 (br m, NHdimer), 7.48-7.64 (br, 1H, triazole-CH), 
7.05-7.48 (br m, 4×5×Phe-CH), 6.35-6.70 (br m, NHunimer), 4.45-6.00 (br m, 11H, 3×Ala-α-H + 
4×Phe-α-H + Lys-α-H + pBA-S-CH + PPBTCR-O-CH2), 3.75-4.45 (br m, n×pBA-O-CH2 + Lys-
CH2-triazole), 2.60-3.45 (br m, 9H + 8H + 2H, 4×Phe-CH2 + 3×Ala-N-CH3 + S-CH2), 0.20-2.60 
(br m, 30×10H + 25H, 30×p(BA)-CH2-CH2-CH3 + 30×pBAbackbone-CH-CH2 + PPBTCZ-CH2-
CH2-CH3 + PPBTCR-CH3 + 3×Ala-α-CH3 + Lys-α-CH2-CH2-CH2); ATR-FTIR νmax cm
-1
: 3307 
(N-Hstr), 3120-2780 (C-Hstr), disappearance of 2095 (N3), 1734 (C=Op(BA)), 1630 (C=OCP-str). Mp 
(SEC-DRI(THF)) = 4900 g·mol
-1
. 
The crude product of conjugate di
NMe
CP-pBA22 (10 mg) in DCM (1.0 mL) was added to I2 
(0.062 g) in DCM (2.0 mL) and stirred for 20 h. The mixture was diluted with DCM and washed 
with an aqueous solution containing EDTA (0.055 M) and sodium thiosulfate pentahydrate 
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(0.053 M) (2×30 mL, pH 8.5) followed by water (30 mL). The resulting yellow solution was 
dried with MgSO4 and concentrated under vacuum. Affording di
NMe
CP-pBA22 as a yellow light-
brown film: 10 mg; 
1
H NMR (300 MHz, CDCl3) δ ppm: 8.35-8.85 (br m, NHdimer), 6.85-7.80 (br 
m, 42H, 40×Phe-CH + 2×triazole-CH), 6.30-6.80 (br m, NHunimer), 4.45-6.00 (br m, 21H, 6×Ala-
α-H + 8×Phe-α-H + 2×Lys-α-H + pBA-S-CH + 2×PPPPTC-O-CH2-triazole), 3.60-4.45 (br m, 
48H, 22×pBA-O-CH2 + 2×Lys-CH2-triazole), 2.60-3.55 (br m, 38H, 8×Phe-CH2 + 6×Ala-N-CH3 
+ PPPPTCz-S-CH2-CH2), 0.20-2.60 (br m, 254H, 22×pBA-CH2-CH2-CH3 + 22×pBAbackbone-CH-
CH2 + PPPPTCR-CH-CH3 + 6×Ala-α-CH3 + 2×Lys-α-CH2-CH2-CH2). ATR-FTIR νmax cm
-1
: 
3304 (N-Hstr), 3120-2800 (C-Hstr), disappearance of 2095 (N3), 1728 (C=Op(BA)), 1630 
(C=OCP-str). 
The crude product of conjugate 
NMe
CP-pSty20 (20 mg) in DCM (2.0 mL) was added to I2 
(0.040 g) and stirred for 18 h. The mixture was diluted with DCM and washed with an aqueous 
solution containing EDTA (0.055 M) and sodium thiosulfate pentahydrate (0.053 M) (2×30 mL, 
pH 8.5) followed by water (30 mL). The resulting yellow solution was dried with MgSO4 and 
concentrated under vacuum then precipitated with MeOH to yield 
NMe
CP-pSty20 as a light brown 
powder: 13.7 mg; 
1
H NMR (500 MHz, CDCl3) δ ppm: 8.30-8.85 (br m, NHdimer), 6.25-7.35 (br 
m, 121H + NHunimer, 100×pSty-CHaromatic + 20×Phe-CHaromatic + CHtriazole + NHunimer), 3.80-5.93 
(br m, 13H, Lys-α-H + 4×Phe-α-H + 3×N-Me-Ala-α-H + PPBTCR-COO-CH2 + pSty-S-CH + 
Lys-CH2-triazole), 0.20-3.40 (br m, 103H, PPBTCz-S-CH2 + 20×pStybackbone-CH-CH2 + PPBTCR-
CH-CH3 + 3×Phe-α-CH2 + 3×N-Me-Ala-N-CH3 + PPBTCZ-CH2-CH2-CH3 + 3×N-Me-Ala-
α-CH3 + Lys-α-CH2-CH2-CH2). ATR-FTIR νmax cm
-1
: 3303 (N-Hstr), 3120-2990 (C-Haromatic-str), 
2990-2820 (C-Halkyl-str), disappearance of 2095 (N3), 1627 (C=OCP-str). 
Mp (SEC-DRI(THF)) = 5600 g·mol
-1
. 
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2.4 Details 
2.4.1 Materials 
Fmoc-L-Lys-OH, Fmoc-L-Lys(Boc)-OH, Fmoc-L-Trp(Boc)-OH, Fmoc-D-Leu-OH, 
Fmoc-L-Ala-OH, Fmoc-D-Phe-OH, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (HBTU), O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (HATU), were purchased from Novabiochem and GL Biochem Shanghai, 
and used as received. 2-Chlorotrityl chloride resin (1 % DVB, 100-200 mesh), and 1-
hydroxybenzotriazole (HOBt) were purchased from Novabiochem and used as received. 2-
Propanoic acid butyl trithiocarbonate (PABTC) and 2-propanoic acid 3-propanoic acid 
trithiocarbonate (PAPATC) were synthesised by Algi Serelis of DuluxGroup. n-Butyl acrylate 
(BA), styrene (Sty), 2,2′-azobis(2-methylpropionitrile) (AIBN), 4-dimethylaminopyridine 
(DMAP), propargyl alcohol, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI), sodium 
azide (NaN3), sulfuryl chloride (SO2Cl2), imidazole, acetyl chloride, paraformaldehdye, p-
toluenesulfonic acid, sodium hydrogen carbonate (NaHCO3), anhydrous magnesium sulfate 
(MgSO4), hydrochloric acid (HCl), sodium hydroxide (NaOH), triethylsilane, piperidine, N-
methyl-2-pyrrolidone (NMP), N,N-diisopropylethylamine (DIPEA), thioanisole, 
triisopropylsilane (TIPS), copper(II) sulphate pentahydrate (CuSO4·5H2O), sodium ascorbate 
(NaAsc), iodine, ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA), sodium 
thiosulfate pentahydrate, neutral alumina, basic alumina, trifluoroacetic acid (TFA), 
hexafluoroisopropanol (HFIP), ethyl acetate (EtOAc), toluene, dioxane, dichloromethane 
(DCM), N,N-dimethylformamide (DMF, peptide synthesis grade), methanol (MeOH), diethyl 
ether, hexane, acetonitrile (ACN) were purchased from Sigma Aldrich, Merck, Ajax, Fluka and 
used as received unless indicated. Where water was required, MilliQ water was used. n-Butyl 
acrylate-d9 (BA-d9) was obtained from Polymer Source. Deuterated solvents were obtained from 
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Cambridge Isotope Laboratories (Novachem). Chloroform-d used for association constant 
experiments were passed through basic alumina before use. Dry solvents (used as indicated) 
were dried by distillation prior to use and kept under N2 for the reaction. BA, BA-d9 and Sty 
were deinhibited before use. 
2.4.2 Equipment 
Preparative reverse phase high-performance liquid chromatography (RP-HPLC) was 
performed on a Waters SunFire C18 5 μm 19 × 150 mm column at 7 mL/min running a linear 
gradient eluent of water and acetonitrile (with 0.01 % TFA in both solvents) with an inline 
Waters 2489 UV-Visible Detector. 
Microwave assisted CuAAC were performed using a CEM Discover SP microwave reactor 
using 5 mL borosilicate microwave vessels. 
Microwave assisted solid phase peptide synthesis was carried out on a CEM Liberty 1, 
automated microwave peptide synthesiser. 
2.4.3 Characterisation 
Nuclear magnetic resonance spectroscopy 
NMR spectra were acquired at 300 K on a Bruker Avance 500, 400, 300, or 200 NMR 
spectrometer operating at 500 MHz, 400 MHz, 300 MHz, or 200 MHz respectively for 
1
H NMR. 
Solvent residual signals were used as an internal reference with the exception of chloroform-d 
where tetramethylsilane was used. 
Determination of Ka: a stock solution of 
NMe
CP1 in CDCl3 (240 μL, 0.02 M) was prepared. 
CDCl3 (400 μL) was added to the NMR tube, then 40 uL aliquots of 
NMe
CP1 were added to the 
vessel, shaken, then followed by data acquisition. Concentrations of 0.005 M, 0.006 M, and 
0.007 M were analysed. Concentrations of dimer and unimer were calculated from the 
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integration of NHdimer (8.34-8.86 ppm) and NHunimer (6.40-6.71 ppm) signals of each sample. The 
Ka reported is the mean value from the 3 samples. 
 
Mass spectrometry 
ESI-LCQ and APCI-LCQ mass spectrometry was undertaken on a Finnigan LCQ. ESI-
FTICR and MALDI-FTICR mass spectrometry was performed on a Bruker 7T Fourier 
Transform Ion Cyclotron Resonance Mass Spectrometer. FTICR was calibrated with 
poly(ethylene glycol) methyl ether standards. MALDI-ToF mass spectrometry was performed 
using a Bruker Daltonics Ultraflex II MALDI-ToF Spectrometer, equipped with a nitrogen laser 
delivering 2 ns pulses at 337 nm with positive ion time of flight detection using an accelerating 
voltage of 25 kV and recorded in reflector mode calibrated with poly(ethylene glycol) methyl 
ether standards (Mn = 2000, 5000 Da). 
MALDI sample preparation: pBA samples were prepared by layering trans-2-[3-(4-tert-
butylphenyl)-2-methyl-2-propenylidene]malononitrile (DCTB, 1 μL from a 10 mg/mL solution), 
followed by sodium trifluoroacetate (1 μL from a 10 mg/mL solution), and the analyte (1 μL 
from a 10 mg/mL solution); pSty samples were prepared by spotting a premixed solution of pSty 
(10 mg/mL, THF)/dithranol (10 mg/mL, THF)/NaI (10 mg/mL, MeOH) in a volume ratio of 
1:2:10. CP1 sample (1 μL) was spotted from a mixture of α-cyano-4-hydroxycinnamic acid 
(CHCA, 100 μL from 10 mg/mL solution in THF)/sodium iodide (10 μL from 10 mg/mL in 
MeOH)/CP1 (20 μL from a 10 mg/mL THF suspension); CP3 sample was prepared by layering 
CHCA (1 μL from 10 mg/mL solution in THF), followed by silver nitrate (1 μL from saturated 
solution in MeOH), and CP3 (1 μL from a 5 mg/mL THF/MeOH (1:1 vol) suspension). 
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High performance liquid chromatography 
Analytical reverse phase high performance liquid chromatography (RP-HPLC) was carried 
out on two instruments: a Phenomenex Jupiter C4 300 Å 150 × 2 mm column running a linear 
gradient eluent of water and acetonitrile (with 0.01 % TFA in both solvents) with inline Finnigan 
LCQ Deca mass spectrometer and Finnigan MAT Spectrasystem UV6000LP detector; and a 
SunFire C18 5 μm 2.1 × 150 mm column running a linear gradient of water and acetonitrile 
(with 0.1 % formic acid in both solvents) with inline Shimadzu LCMS-2020 and Shimadzu SPD-
20A UV/Vis detector. 
Size exclusion chromatography (SEC) was performed with an inline Shimadzu RID-10A 
Refractive Index Detector with THF + hydroquinone (0.05 %wt) and toluene (0.5 %vol) as the 
flow rate marker at 40 °C and DMF + LiBr (0.1 %wt) + hydroquinone (0.05 %wt) and water 
(1.15 %wt) as the flow rate marker at 50 °C on Polymer Laboratories (PL) 10 μm guard column 
with two PL Mixed-B columns and PolarGel 8 μm guard column with two PL PolarGel columns 
respectively at a flow rate of 1 mL/min and 0.5 mL/min. Samples were filtered through a PTFE 
filter (0.45 μm) prior to injection, injection volume 100 μL. Reported values are based on narrow 
polystyrene standards in the range of 1260-6035000 Da and 580-38640 Da. 
 
Polarimetry 
Specific rotation values were deduced using an ATAGO Polax-2L polarimeter. 
 
Vibrational spectroscopy 
Vibrational spectroscopy was carried out on two instruments: a Bruker IFS66V FTIR using a 
mid-range beam splitter with a single bounce diamond/KRS-5 ATR accessory and the system 
purged with N2; and a Bruker Alpha-E ATR-FTIR spectrometer with a ZnSe crystal. 
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Small angle neutron scattering 
Small angle neutron scattering (SANS) measurements were performed on the NG3 beamline 
at the National Institute of Standards of Technology Center for Neutron Research in 
Gaithersburg, MD, USA. Raw data was corrected for detector sensitivity, background and empty 
cell scattering.
[150]
 Sample-to-detector distances of 1.33 m and 8 m were used and the data 
combined for 0.0057 Å
-1
 ≤ q ≤ 0.43 Å-1. Where removed, incoherent scattering was subtracted 
using the Porod Law (I(q)·q
4
 vs q
4
 plot). 
Sample preparation: CP1-pBA30 (1 mM) samples in TFA-d/THF-d8 (1:9vol and 9:1vol) and 
TFA-d/CDCl3 (1:9vol and 9:1vol) mixtures were prepared from mixing appropriate volumes of 
CP1-pBA30 (1 mM in TFA-d), CP1-pBA30 (1 mM in THF) and CP1-pBA30 (1 mM in CDCl3) 
then transferred to Hellma cells (with 2 mm path length) for data acquisition. An additional 
sample involving the solvent mixture TFA-d/THF-d8 (1:9vol) was prepared by dissolving CP1-
pBA30 in TFA-d and diluting with THF-d8 (as opposed to mixing two solutions of CP1-pBA30). 
‘Capping’ experiments: A chloroform-based solution of the monotopic additive (NMeCP1, 
NMe
CP1-pBA16, 
NMe
CP1-pSty20) was divided to achieve 1, 1 and 2 equivalents relative to CP1-
(p(BA-d9)29)2 and solvent was removed in vacuo. The analyte solution was then transferred to 
dissolve the desired additive, and the analytical treatment is repeated for each of the ratios tested 
relative to CP1-(p(BA-d9)29)2; 1:0, 1:1, 1:2, 1:4 ([CP]/[
NMe
CP]). Control samples (0:0, 0:1, 0:2, 
0:4 ([CP]/[
NMe
CP]) were prepared in the same manner by using pure THF-d8 to dissolve the 
desired additive. Scattering intensities from the control samples were subtracted from the 
corresponding scattering intensities of the samples. 
Models incorporated in the NCNR analysis macro were used to fit to the collected data. 
General procedure followed for fitting: uniform hard sphere model was used as a first attempt for 
fitting, where necessary, this was followed by polydisperse spheres, uniform ellipsoids, uniform 
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Table 2.1: Diagrams of the modelled geometries used in the SANS analyses. 
Sphere 
 
 
 
Ellipsoid 
(left: needle-like; right: disk-like) 
 
 
 
Cylinder 
 
 
 
Core-shell cylinder 
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Table 2.2: Scattering length densities of solvents and solvent mixtures used in the study determined using 
the NCNR SLD calculator.
[151]
 
Solvent/solvent mixture 
Calculated scattering 
length density (×10
-6
 Å
-2
) 
DMSO-d6 5.28 
TFA-d 3.00 
THF-d8 6.35 
CDCl3 3.16 
TFA-d/THF-d8 (1:9 v/v) 6.02 
TFA-d/THF-d8 (9:1 v/v) 3.34 
TFA-d/CDCl3 (1:9 v/v) 3.02 
TFA-d/CDCl3 (9:1 v/v) 3.14 
 
cylinders, polydisperse cylinders, and core-shell cylinders to gain further insight (see Table 2.1). 
The parameters: scale, solvent scattering length density (SLD) and incoherent background were 
always fixed while the other parameters were left to float. Scale was determined by the volume 
fraction of the sample; solvent SLDs were determined by the equation:     
∑    
 
   
  
 where     
is the bound coherent scattering length of ith of n atoms in a molecule with molecular volume    
with literature values of scattering lengths and cross sections
[152]
 using the NCNR SLD calculator 
(see Table 2.2);
[151]
 SLDs of solvent mixtures were determined by weighted averages (see Table 
2.2), and incoherent background scattering was determined using the Porod Law (I(q)·q
4
 vs q
4
 
plot). Repeated fittings with various manually input starting parameters were used to assess the 
validity of the fit. In the case of the ‘dimer’ model, a uniform cylinder model was used with the 
radius and length parameters fixed to 5 Å and 10.2 Å respectively; only the cylinder SLD 
parameter was left variable. 
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Thermogravimetric analysis 
Thermogravimetric analysis (TGA) was carried out on a TA Instruments Hi-Res TGA 2950 
Thermogravimetric Analyzer purged with nitrogen gas using a platinum crucible. Conjugate 
samples were transferred with DCM, temperatures were increased from 25 °C to 700 °C at 
10 °C/min and held at 50 °C for 10 min to remove residual DCM from transferring. 
 
Ultraviolet/visible absorption spectroscopy 
UV/Vis absorption spectroscopy was carried out on a Varian Cary 4E UV-Visible 
Spectrophotometer. 
 
Transmission electron microscopy 
Transmission electron microscopy (TEM) was performed on a Phillips CM120 Biofilter 
Electron Microscope, where samples were prepared by depositing a drop of the sample in THF 
(0.2 mM), without staining, onto a carbon coated Formvar film copper grid and dried at ambient 
conditions. 
 
Dynamic light scattering 
Dynamic light scattering (DLS) measurements were obtained using a Zetasizer Nano from 
Malvern Instruments with a 4 mW, 633 nm laser and a detector angle of 173°. The analysis of 
each sample is the result of 8 runs with the correlation functions fitted by the non-negative least 
squares method. When temperatures varied, an equilibration time of at least 5 minutes were 
given to the samples (with the exception of monotopic addition experiments). 
Addition of monotopic species: a solution of di
NMe
CP1-pBA22 in filtered THF (0.2 mM) was 
prepared and analysed by DLS. A THF-based solution of the monotopic additive (
NMe
CP1 or 
NMe
CP1-pBA16 (I2 treated)) was divided to achieve 1, 1 and 18 equivalents relative to di
NMe
CP1-
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pBA22 and solvent was removed in vacuo. DLS analyses were done at 20 °C, 40 °C, and back to 
20 °C. The analyte solution was then transferred to dissolve the desired additive, and the 
analytical treatment is repeated for each of the ratios tested relative to di
NMe
CP1-pBA22; 1:0, 1:1, 
1:2, 1:20. Samples were kept at 40 °C for at least 20 minutes for equilibration before acquisition. 
 
Static light scattering 
Static light scattering (SLS) experiments were done on a Brookhaven laser light scattering 
system. A 633 nm laser was used and the sample was kept at 25 °C throughout the experiment. 
Dark count rate was recorded, distilled and filtered toluene (n = 1.491, Rθ = 1.398 × 10
-5
) was 
used to calibrate the instrument and filtered THF (n = 1.409) was used as a blank prior to the 
measurements. Mw was obtained with a Berry plot using the Brookhaven Instruments Zimm Plot 
Software (BI-ZPW). Specific refractive index increment (dn/dc) = 0.057 for poly(n-butyl 
acrylate) in THF at λ = 633 nm at 25 °C[153,154] was used as an approximation for the dn/dc of 
CuNP-free conjugate 
NMe
CP1-pBA16 and CuNP-free conjugate di
NMe
CP1-pBA22. CuNP-free 
conjugate 
NMe
CP1-pBA16 was analysed at concentrations of 19.5, 9.7, 4.9 and 2.4 mg/mL (5.9, 
2.9, 1.5, 0.7 mM respectively) in filtered THF in a quartz cell at angles 15°-115° taking 5×1 sec 
intensity measurements at every 5° increment. CuNP-free conjugate di
NMe
CP1-pBA22 was 
analysed at concentrations of 10.2, 5.1 and 2.6 mg/mL (2.0, 1.0, 0.5 mM respectively) in filtered 
THF in a quartz cell at angles 15°-115° taking 5×1 sec intensity measurements at every 5° 
increment. 
 
Differential scanning calorimetry 
Differential scanning calorimetry (DSC) was carried out on a Mettler Toledo DSC823e. 
NMe
CP1 (1.7 mg), pBA16-alkyne (5.0 mg), pBA30-alkyne (4.1 mg), pBA22-dialkyne (3.1 mg), 
pSty20-alkyne (1.3 mg), 
NMe
CP1-pBA16 (3.8 mg), 
NMe
CP1-pBA30 (1.1 mg), di
NMe
CP1-pBA22 
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(3.7 mg), and 
NMe
CP1-pSty20 (1.6 mg) was analysed in an aluminium crucible with a pinhole 
against a reference crucible of the same setup. In the case of liquid conjugates (i.e. 
NMe
CP1-pBA16, 
NMe
CP1-pBA30 and di
NMe
CP1-pBA22) the sample was transferred using 
chloroform as a solvent which was subsequently removed using a flow of N2 gas. At a rate of 
10 °C/min, samples were heated to 100 °C, then 3×(cooled to -100 °C, isothermal for 
10 minutes, heated to 100 °C). 
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3 (Cyclic peptide)-polymer conjugate nanotubes 
3.1 Introduction 
The ability of cyclic peptides to self assemble through interannular hydrogen bonding, i.e. 
stacking of cyclic peptides, leads to nanotube structures. Nanotubes have found increasing 
attention in nanotechnology with applications such as drug delivery media, antibacterials, 
sensors, ion/molecular channels, due to their anisotropic structure, rigid structure and internal 
channel.
[155-160]
 While there are covalent-based routes (notably, bottlebrush copolymers
[161-166]
 
and carbon nanotubes
[167]
), the performance of natural systems like gramicidin A,
[168,169]
 
α-hemolysin,[170] and the tobacco mosaic virus,[171,172] which are capable of such precise 
manufacturing of nanotubes as well as enabling dynamic/reversible properties, are highly 
inspiring incentives for taking a supramolecular approach. It has been possible to artificially 
imitate these supramolecular routes to nanotubes
[160,173]
 through the helical coiling of linear 
strand(s),
[174-177]
 the stacking of rings/macrocycles beyond cyclic peptides,
[178-186]
 and the 
organisation of sectors.
[28,187-191]
 
In the case of cyclic peptides, controlling the lengths of extended nanotube structures (i.e. 
beyond dimerisation) is a difficult task due to the cooperative growth mechanism. Recently, 
control over the length has been achieved using a layer-by-layer like approach,
[51]
 but is limited 
to obtaining relatively short nanotubes. The proposed templating approach by Granja et al.
[52]
 is 
another interesting method, similar to the templating of preorganised segments
[28,172] 
and the 
threading of macrocycles,
[178,192]
 where the nanotube length depends on the chain length of the 
guest molecule, but such an approach is less effective for applications that wish to take 
advantage of using the internal channel of the nanotube. There have been reports on the use of 
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polymers tethered to CPs to influence the length of assembly and observing the structures in the 
dry state using microscopic techniques.
[117,120,134]
 In recent work carried out by our group, the 
added functionality of conjugating polymers facilitating solubility has consequently allowed 
characterisation of the structure in solution through the use of small angle neutron scattering 
(SANS), which is ideal in a dynamic system to avoid misrepresentation of the structure due to 
sample preparation (e.g. increasing concentration during drying, affinity to substrate, etc.). In 
this manner we were able to recognise the influence of the polymer on the nanotube length.
[139]
 It 
should be noted that in order to obtain the contrast needed for SANS analyses, deuterated 
solvents as opposed to hydrogenous solvents are required. While this now presents a different, 
but still misrepresentative, characterisation of the system, electron microscopy imaging of 
locked-in CP-polymer conjugates and SANS analyses of deuterium rich samples in a 
hydrogenous dispersant suggests that the assembly is of a rigid rod structure.
[139]
  
3.2 Chapter aim 
This chapter presents the study of manipulating the self assembly of cyclic peptides by 
altering chemical functionality and chemical environment. Specifically, the impact of: grafting 
poly(n-butyl acrylate) to the cyclic peptides; the solvents and solvent mixtures in their 
competition for H-bonding sites as well as differing polymer solvation strengths; and variations 
to the cyclic peptide residues comparing side chains of polar and non-polar nature. 
3.3 Assembly of unconjugated CP 
As described in previous publications
[133-135]
 (see Chapter 2 for experimental details), a range 
of self assembling cyclic peptides containing azide moieties were obtained from Fmoc- solid 
phase peptide synthesis (SPPS) and a range of polymers containing an alkyne functional group at 
the α-terminus by reversible addition-fragmentation chain transfer (RAFT) polymerisation. In 
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Scheme 3.1: Synthetic strategy for the formation of (cyclic peptide)-polymer conjugates. 
 
order to obtain the highest grafting conversion with minimal excess polymer (as found by a 
previous study),
[135]
 CPs and polymers were then conjugated by microwave assisted copper(I)-
catalysed azide-alkyne cycloaddition (CuAAC) using a high concentration of copper catalyst 
(see Scheme 3.1). 
First we examine cyclo[(Lys(N3)-D-Leu-Trp-D-Leu-)2] CP1, which has two azide containing 
residues to introduce polymers with alkyne end-groups. A very limited range of solvents can be 
used to obtain macroscopically clear solutions (i.e. submicron sizes) of unconjugated CP1. 
Trifluoroacetic acid (TFA) and dimethylsulfoxide (DMSO) are commonly used solvents to 
dissolve CPs containing these residues.
[47,64,74,134,135]
 Small angle neutron scattering (SANS) 
enables direct analysis of the macroscopically dissolved CP1 in TFA-d and DMSO-d6 (Figure 
3.1). 
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Figure 3.1: SANS data of CP1 in TFA-d and DMSO-d6. CP1 is molecularly dissolved in TFA-d but 
forms 1-15 nm structures in DMSO-d6. The figure shows the fit of a uniform ellipsoid model (disk-like) 
to CP1 in DMSO-d6 (4 mM). This has been interpreted as bundles of short tubes in DMSO-d6. See 
Figures A.1-A.3 for model fitting. 
 
In TFA-d, CP1 does not scatter beyond the incoherent scattering from the solvent. This 
suggests that any structure in solution is smaller than 1 nm, corresponding to the molecular 
dissolution of CP1. On the other hand, the scattered intensity I from CP1 in DMSO-d6 changes 
as a function of scattering vector q over the probed q-range. The scattering function I(q) has been 
fitted with a uniform ellipsoid model with disk-like geometry with r ~ 13 nm and rrotation-
axis ~ 3 nm (see Figures A.1-A.3 for details on the modelling).
[150]
 These dimensions are larger 
than expected for a single CP1 nanotube (which would have a radius~0.5 nm), but in line with 
earlier observations by Ghadiri et al. who showed electron (and optical) microscopy images of 
unconjugated CPs in bundles (microcrystals).
[39,47,71]
 From this, we rationalise that CP1 exists as 
bundles of short tubes in DMSO-d6, a concept that has also been proposed in the study of CP ion 
channel mechanism.
[57,58,193]
 Indeed, while early work in the field presented the mechanism of 
ion transport through the internal cavities of cyclic peptide nanotubes,
[61,69]
 assembly into ‘barrel 
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and stave’ structures have also been suggested (see Sub-chapter 1.2.7).[59] Furthermore, the work 
of Ramesh et al. and Kodama et al. have shown that the transport of ions is possible with cyclic 
peptides with only 4 or 6 residues, for which the internal pore is too small to allow ion transport, 
thus suggesting a barrel and stave assembly.
[57,58,193]
 
3.4 Solvent influence on self assembly 
Using microwave assisted CuAAC, we conjugated CP1 with two chains of alkyne-
functionalised poly(n-butyl acrylate) (pBA30-alkyne; Mn 4100 g·mol
-1
, DP 30, Đ 1.16) yielding 
CP1-(pBA30)2. We probe the effect of the solvent environment on the assembly of the (cyclic 
peptide)-polymer conjugates, using a variety of solvents and mixtures to empirically correlate the 
influence of the solvent H-bonding strength in competition with H-bonding between CPs, and 
the solvent quality towards the peptide and polymer. 
Remarkably, unlike CP1, peptide-polymer conjugate CP1-(pBA30)2 in TFA-d shows an 
assembly of appreciable size by SANS (Figure 3.2). This is likely due to the polymer shielding 
the peptide from the TFA-d molecules, a phenomenon studied in greater details by the 
modification of the polymeric chain length.
[139]
 The profile can be fitted with small (< 10 nm), 
anisotropic geometry models such as ellipsoids or short cylinders with low aspect ratios (Figures 
A.4-A.5). CP1-(pBA30)2 was difficult to solubilise in DMSO-d6 and this is reflected in the steep 
I α q-4 relationship at q < 0.03 Å-1 corresponding to Porod scattering of large particles (Figure 
3.2).
[194,195]
 Due to the poor solubility of pBA in DMSO, it is understandable that this property is 
translated to the conjugate. More interestingly, we see a coexistence of precipitate and low 
aspect ratio structures in DMSO-d6. Despite the disparity between DMSO-d6 and the pBA 
chains, the assemblies remain short. Where assembled, the dimensions of the fitted geometries of 
CP1 and CP1-(pBA30)2 are very different. The scattering profiles of CP1-(pBA30)2 in DMSO-d6 
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Figure 3.2: SANS data of CP1-(pBA30)2 in TFA-d and DMSO-d6. CP1-(pBA30)2 exists as short 
individual tubes. Precipitation is observed for the conjugate in DMSO-d6. See Figures A.4-A.5 for model 
fitting. 
 
 
Figure 3.3: SANS data of CP1-(pBA30)2 in CDCl3 and THF-d8. Conjugate exists as long and individual 
tubes. See Figure A.6 for model fitting. 
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and TFA-d can be well described with a cylinder model where r ~ 1 nm. More complex models, 
to account for a solvent penetrable shell, was unnecessary to give a good fit to the data; however 
the obtained radii and SLDs must be interpreted as an average of the peptide core and solvated 
polymer shell. The fact that the obtained radii is only marginally larger than expected of a single 
unconjugated cyclic peptide nanotube which cannot account for the full length of the polymer 
chain, shows not only the low contrast of the polymer but is also evidence of ‘isolated’ cyclic 
peptide nanotubes (i.e. not bundled) presumably sterically stabilised by the polymer chains. 
These findings match previous SANS analyses done on these systems.
[139]
 
Since the conjugation of a polymer provides solvent solubility to the nanotubes, the 
conjugate CP1-(pBA30)2 was dissolved in tetrahydrofuran-d8 (THF-d8) and chloroform-d 
(CDCl3). In these solvents H-bonding between CPs are promoted, and indeed we observe a 
scattering power law of q
-1
 (Figure 3.3), characteristic of the intermediate regime of rigid rods. 
With the plateau to the Guinier regime beyond the lowest q probed, fitting the data gave 
cylinders with very high aspect ratios, length >110 nm and radius ~ 1 nm (Figure A.6). This 
finding supports the notion of a cooperative assembly mechanism, where the equilibrium 
constant is dependent on the existing length of assembly, as opposed to an isodesmic growth 
mechanism in which the equilibrium constant is identical at all assembly lengths (see Scheme 
3.2).
[46]
 The number average and weight average degree of polymerisation <DP>n and <DP>w, 
respectively, of a supramolecular assembly with a single nucleation step can be described:
[196]
 
 〈  〉  
           [ ]  
     [ ]           [ ]  
 (3.1) 
 〈  〉  
     [ ]           [ ]  
     [ ]           [ ]  
 (3.2) 
 
Where σ = K2/K; [A] is the concentration of unassembled monomer, K2 is the equilibrium 
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Scheme 3.2: Illustrating the concept of two supramolecular growth mechanisms: (a) isodesmic growth, 
with association constant K; and (b) single-step cooperative growth, where nucleation takes place at two 
units with association constant K2 and elongation takes place beyond two units with association constant 
K. Note: Mass balancing between the equations has omitted for clarity. 
 
constant for the addition of two unassembled monomers to form a dimer, and K is the 
equilibrium constant for the addition of one monomer to an assembly with two units or more. 
Based on the thermodynamic studies of partially N-methylated CPs (monotopic species), the 
highest equilibrium constants for the formation of dimers have been found to be in the order of 
2000 M
-1
 in CDCl3.
[45]
 For an isodesmic supramolecular polymerisation (i.e. K2 = K) with 
association constant K ~ 2000 M
-1
 at 1 mM, the <DP>w ~ 3 (length ~ 1.5 nm
†
).
[196] 
This is 
significantly shorter than the assembly observed by SANS. If we however assume a cooperative 
growth mechanism (in the simplest case of a nucleation step at 2 units, i.e. K2 < K) and an 
association constant for the first two units of the assembly K2 ~ 2000 M
-1
, then to obtain a 
<DP>w ~ 220 (length ~ 110 nm
†
) we can estimate the equilibrium constant for subsequent 
growth K to be greater than 160 000 M
-1
 (Figure 3.4).
[196]
 
                                                 
†
 A length of 5 Å per unit
[39]
 has been used to estimate the length of assembly from DP. 
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Figure 3.4: Theoretical number and weight average degree of polymerisation <DP>n and <DP>w with 
monomer concentration for isodesmic and cooperative growth mechanisms.
[196]
 A cooperative growth 
mechanism is used to explain the long assembly at 1 mM. 
 
To probe solvent conditions between these two extremes, solvent mixtures of TFA-d/THF-d8 
and TFA-d/CDCl3 were used. Table 3.1 shows the results of these experiments (see Figures 
A.4-A.9 for scattering profiles and model fitting). With just 10 vol% TFA-d the assemblies are 
found to be significantly shorter than those observed in neat THF-d8 or CDCl3 and yield 
comparable dimensions to our previous findings with the same solvent composition.
[139]
 A closer 
look at the fitted parameters for radius and contrast of CP1-(pBA30)2 in the pure solvents 
suggests that the polymer chains are more solvated in CDCl3 (by the larger radius and lower 
contrast) than in THF-d8 (smaller radius and higher contrast). This difference in solvation could 
explain the observed differences in assembly lengths between TFA-d/THF-d8 (1:9 v/v) and 
 
Table 3.1: Length parameter from fitting uniform cylinder model to scattering profiles of CP1-(pBA30)2 
at 1 mM in various solvent mixtures. See Figures A.4-A.9 for scattering profiles and model fitting. 
Solvent composition, TFA-d (vol%) 100 90 10 0 
Length in TFA-d/THF-d8 (nm) 10 10 30 > 110 
Length in TFA-d/CDCl3 (nm) 10 10 10 > 110 
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TFA-d/CDCl3 (1:9 v/v); as we have established that the polymer shields the CP from TFA-d, one 
could expect that a better solvated polymer would be more permeable to TFA molecules. An 
experiment was carried out to test the effect of the order of solvent addition. CP1-(pBA30)2 was 
dissolved in TFA-d then diluted with THF-d8 to a final solvent mixture of TFA-d/THF-d8 
(10 vol%). In this case even shorter tubes were observed, leading to the conclusion of a non-
thermodynamic product (Figure A.9) of which the details require further studies. 
3.5 CP influence on self assembly 
A key feature of using self assembling cyclic peptides is their versatility in chemical 
functionality by the inclusion of residues with various functional groups. Here we use CP2, 
which substitutes (from CP1) the two Trp residues for two Lys(Boc), as a model compound that 
might be potentially used to functionalise the immediate shell of a tube (i.e. conjugated to the 
peptide and not the polymer). Attempts to conjugate pBA30-alkyne to CP2 by microwave-
assisted CuAAC resulted in conversion < 100 % as judged by ATR-FTIR (Figure 3.5). We have 
attributed this difference in conjugation efficiency due to the bulky Boc protecting groups which 
reduce the accessibility of the sites (based on our findings of attempting to conjugate 4 polymers 
to a CP with 4 azide sites).
[135]
 Conjugation efficiency of pBA30-alkyne to Boc-deprotected CP2, 
i.e. CP3, was difficult to ascertain due to the relative insolubility of CP3 which biased the 
observation of the conjugate. Our uncertainty with conversion led us to synthesise samples 
where the cyclic peptide was in excess over the polymer during conjugation, to observe if a 
higher number of unconjugated sites would impact the assembly. Conjugates CP2-(pBA30)2, 
CP2-(pBA30)1.5 (2.1 eq and 1.5 eq of polymer used respectively) and CP3-(pBA30)2, 
CP3-(pBA30)1.5 (2.1 eq and 1.5 eq of polymer used respectively) in CDCl3 were characterised by 
SANS to assess the impact of assembly by changing residue functional groups on the CP 
assembly (Figure 3.6). It is clear from the scattering profiles that the structures of these two 
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conjugates differ from the CP1 based conjugates. With the difficulty of obtaining information by 
an imagining technique to accompany the data (due to affecting the structure during sample 
preparation and a lack of contrast), the following interpretation is based on our understanding of 
CP1 and CP1-polymer conjugates. Firstly, rigid rod structures can be fit to the scattering data 
over specific q-ranges for all conjugates by the observed I α q-1 relationship (Figure 3.6). CP2-
based conjugates show a steep region (0.03 Å < q < 0.06 Å) and a q
-1
 power law of rigid rods 
(q < 0.03 Å
-1
) (see Figure A.10 for model fitting). A cylindrical model did not fit the data well 
without the additional parameter of polydispersity in the radial component. A Schultz 
polydispersity of ca. 1.0 to the radial component gave a good fit to the data (see Figure A.11 for 
model fitting), which we hypothesise is a result of the incomplete conjugation and the 
consequent tendency of the tubes to partially bundle. This value of radial polydispersity is 
expected as the aggregation of even two tubes will be statistically significant when compared to 
an isolated tube. The scattering traces of conjugates of CP3 were similar to CP1-(pBA30)2 at 
q > 0.02 Å which indicate the presence of cylinders, except at q < 0.02 Å where a steep I α q-3.6 
 
 
Figure 3.5: ATR-FTIR of CP2 (control), CP2-p(BA30)1.5 and CP2-p(BA30)1.5 showing incomplete 
conjugation. 2097 cm
-1
 (azidestr), 1729 cm
-1
 (C=OpBA-str), and 1624 cm
-1
 (C=Opeptide-str). 
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Figure 3.6: SANS data of CP1-(pBA30)2, CP2-(pBA30)2, CP2-(pBA30)1.5, CP3-(pBA30)2, CP3-(pBA30)1.5, 
in CDCl3. Variation of peptide and variation of polymer equivalents used during conjugation. See 
Figures A.10-A.11 for model fitting. 
 
relationship was observed, approaching the Porod scattering of large particles.
[194,195]
 This could 
be the result of the use and incompatibility of CDCl3 as the solvent and the polar nature of the 
lysine residues in the CP3 conjugates. Also of note, in both CP2 and CP3 conjugates, the 
difference between using 2.1 and 1.5 equivalents of polymer per CP during the conjugation 
reaction has a minimal impact on the final assembly. For conjugations involving CP2, this would 
imply a maximum grafting efficiency below 1.5 polymers per CP. 
3.6 Chapter conclusion 
We have shown the direct characterisation of nanotube forming (cyclic peptide)-polymer 
conjugates in a variety of conditions. Fitting the form factor with cylindrical models suggests the 
attachment of pBA can sterically stabilise the assembly, preventing the formation of bundles as 
otherwise observed in the assembly of the unconjugated cyclic peptide in DMSO-d6. 
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Interestingly, in the case of the conjugate in DMSO-d6, large structures were also observed to 
coexist with isolated tubes, such a complex behaviour likely to be the related to the 
incompatibility of pBA with DMSO. In TFA-d, where there was no assembly of the 
unconjugated cyclic peptide, the polymer promoted the formation of (short) tubes in the 
conjugate, a phenomenon we have attributed to the polymer chains shielding the solvent from the 
CP hydrogen bond donors and acceptors. This notion was further explored by using solvent 
mixtures varying in their ability to compete with the H-bonding between CPs. It was found that 
10 vol% TFA-d was enough to significantly shorten the length of the assembly from a non-polar 
solvent. Lastly we explored the variation of the residues of the CP from Trp to Lys(Boc) or Lys, 
where an observable difference was found between the resulting self assembled structure for 
each of these species. Specifically, the incomplete conjugation due to Lys(Boc) residues led to 
partial lateral aggregation; in the case of Lys residues, while unbundled nanotubes were 
observed, aggregates were also present in chloroform-d which have been attributed to the polar 
nature of the Lys residues. 
While the conditions we have varied have offered some degree of control over the length of 
the assembly, an alternative approach is to use partially N-methylated cyclic peptides as 
monotopic species to ‘cap’ and act as ‘chain stoppers’ to the nanotubes. The following chapters 
will explore this option for controlling nanotube lengths. 
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4 (N-Methylated cyclic peptide)-polymer 
conjugates 
4.1 Introduction 
Selective N-methylation of the cyclic peptide backbone provides an efficient route to 
controlling assembly on only one face of the peptide. This approach has previously been 
employed to limit the supramolecular polymerisation of cyclic peptides, providing dimeric 
structures that have been used as model systems to understand the assembly into nanotubes 
(Sub-chapter 1.2.1).
[43-45,72,73,77,82,84,101-103,107,197-199]
 We were interested in the potential use of 
conjugates of such peptides with polymers to act as a ‘cap’ for our nanotubes, to both add tube-
end functionality and possibly control the tube length. However, before exploring binary 
mixtures of 
NMe
CP conjugates and nanotube forming conjugates (Chapter 5), we first focused on 
the self assembly between 
NMe
CP conjugates. As a direction for our study, we envisaged that the 
attachment of N-methylated cyclic peptides to both α- and ω- end-groups of homotelechelic 
polymers would provide a simple system capable of supramolecular polymerisation through the 
dimerisation of these self-complementary end-groups to guide the polymeric spacer. It should be 
noted that many groups have already developed main-chain supramolecular polymers as self-
healing and dynamic/responsive materials.
[34,200-204]
 Among these, two systems are particularly 
relevant to this study. 
Firstly, Ghadiri et al. established that supramolecular polymers could be prepared by 
covalently linking two 
NMe
CPs (Ka ~ 1000 M
-1
)
 
to a short azobenzene moiety showing their use 
beyond just models for analogous extended nanotubes.
[110,111]
 Secondly and more recently, 
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Isimjan et al. prepared and used peptidomimetic oligomers (containing azacyclohexenone 
residues)
[205]
 as rigid, monotopic moieties capable of dimerising through H-bonding.
[206]
 By 
varying the length of the peptidomimetic oligomer (and consequently number of H-bond sites), a 
range of association constants (Ka) were investigated. These self-complementary groups were 
conjugated to end-groups of short poly(ethylene oxide) chains (molecular 
weight ~ 3400 g·mol
-1
). Peptidomimetic oligomers with Ka ~ 1000-10000 M
-1
 were reported to 
drive the assembly of main-chain supramolecular polymers, while an insignificant amount of 
assembly was observed for end-groups with Ka ~ 100 M
-1
.
[206]
 With these reports in mind, one 
would expect the dimerisation of 
NMe
CPs, as end-groups to a short polymeric chain, to drive the 
assembly of main-chain supramolecular polymers. Instead, our investigation revealed a system 
with a deeper complexity than might be expected, as the final structures arising from the 
conjugates were not only dependent on the self assembly of the N-methylated cyclic peptides via 
H-bonds, but also through their uncontrolled aggregation by interactions reminiscent of protein 
aggregation. 
 
4.2 Chapter aim 
This chapter explores the self assembly of partially N-methylated cyclic peptides, in 
particularly the first reported study of 
NMe
CP-polymer conjugates. To set the stage for using these 
unique compounds as chain stoppers for cyclic peptide nanotubes, we aim to show the ability of 
the conjugates to dimerise through the cyclic peptide motif and the limitations of this ability by 
varying the components of the system. We investigate the effect on the assembly by altering the 
chain length and chemical functionality of the polymer, with one extreme example where a 
telechelic polymer was used to study a ditopic 
NMe
CP conjugate.  
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4.3 Monotopic assembly 
Of the alt(D,L)-α-residue based CP compounds reported to date, 
cyclo[(-L-Phe-N-Me-D-Ala)4-] has one of the highest dimerisation constants  (Ka = 1260-
2540 M
-1
 in CDCl3, 293 K)
[43-45] 
and has previously been modified to allow an investigation of 
photochromic supramolecular systems.
[110,111] 
We opted to synthesise a modified version of this 
structure, in which one of N-methyl alanine residue was replaced by an azido-lysine residue to 
allow attachment of the resulting cyclic peptide 
NMe
CP1 to a polymer with two alkyne end-
groups via a dual copper(I)-catalysed azide-alkyne cycloaddition (CuAAC) reaction (see Chapter 
2 for experimental details). 
NMe
CP1 was prepared by the head-to-tail cyclisation of the linear 
peptide precursor 
NMe
LP1 (prepared on 2-chlorotritylchloride resin using standard solid phase 
peptide synthesis techniques) upon treatment with HBTU in dilute DMF solution. Evidence for 
the ability of 
NMe
CP1 to form β-sheet structures was obtained by Fourier transform infrared 
spectroscopy. Signals at 1622 cm
-1 
(amide I) and 1217 cm
-1 
(amide III) are comparable with 
literature ranges of β-sheet structure. Absorption observed at 1680 cm-1 is indicative of 
antiparallel β-sheet structure. Furthermore, absorption at 3300 cm-1 (NH) can be correlated to a 
NH···O bond distance of 3.00 Å
[207] 
which is comparable to other previously studied 
N-methylated cyclic peptides.
[42]
 
The dimerisation of 
NMe
CP1 was investigated by 
1
H NMR spectroscopy in CDCl3 at 300 K. 
Spectra of 
NMe
CP1 contained signals attributable to the amide protons of the hydrogen bonded 
dimeric (NHdimer) as well as the unimeric (NHunimer) species. The ratio of dimeric to unimeric 
species was observed to depend on the concentration of cyclic peptide (Figure 4.1) and the 
dimerisation constant was determined to be 1700 M
-1
 in CDCl3 at concentrations of 
0.005-0.007 M at 300 K. This is comparable to the Ka of the analogous cyclic peptide reported 
by Ghadiri et al. (Ka = 1260-2540 M
-1
),
[43-45]
 indicating that the removal of one of the N-methyl 
groups and the inclusion of the azide did not interfere with the dimerisation process. Note that 
4 – (N-Methylated cyclic peptide)-polymer conjugates 
75 
 
the broad peaks observed in the 
1
H NMR spectra of 
NMe
CP1 in CDCl3 are due to the presence of 
multiple conformers, similar peaks are observed in THF-d8. However, the addition of LiBr, 
which is well known to disrupt hydrogen bonding in peptide structures,
[208,209]
 to a solution of 
NMe
CP1 in THF-d8 resulted in sharper peaks in the 
1
H NMR spectrum of the cyclic peptide 
(Figure 4.2), suggesting that complexation of Li
+ 
ions results in a single peptide 
conformation.
[210-212] 
In addition, the signals attributable to the amide protons shifted downfield 
and were well resolved. 
Having demonstrated that 
NMe
CP1 can hydrogen bond into dimers, we investigated the effect 
of tethering polymers to the cyclic peptide and the impact of this on self assembly. A series of 
alkyne termini poly(n-butyl acrylate) of varying degrees of polymerisation (DP) was synthesised 
by the polymerisation of n-butyl acrylate (BA), mediated by alkyne functional RAFT agents 
 
 
Figure 4.1: 
1
H NMR spectra of 
NMe
CP1 in CDCl3+TMS (solvent passed over basic alumina before use). 
(a) 0.005 M, (b) 0.006 M, (c) 0.007 M. Concentrations of dimer and unimer were calculated from the 
integration of NHdimer (8.34-8.86 ppm) and NHunimer (6.40-6.71 ppm) signals of each sample. The Ka 
reported is the mean value from the 3 samples. 
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Figure 4.2: 
1
H NMR of 
NMe
CP1 (THF-d8, 0.005 M) with varying LiBr concentration: (a) 0 M, (b) 
0.009 M, (c) 0.043 M. i.e. [
NMe
CP1]:[LiBr] of (a) 1:0, (b) 1:2, (c) 1:9. 
 
PPBTC or PPPPTC; to yield pBA16-alkyne (Mn 2300 g·mol
-1
, DP 16, Đ 1.15), pBA30-alkyne 
(Mn 4100 g·mol
-1
, DP 30, Đ 1.16) and pBA22-dialkyne (Mn = 3200 g·mol
-1
, DP 22, Đ 1.14). 
Polymers pBA16-alkyne, pBA30-alkyne, and pBA22-dialkyne were conjugated to 
NMe
CP1 using 
a microwave assisted, copper mediated azide-alkyne cycloaddition (CuAAC) reaction, to yield 
peptide polymer conjugates 
NMe
CP1-pBA16, 
NMe
CP1-pBA30 and di
NMe
CP-pBA22, respectively 
(Scheme 4.1). 
The microwave mediated CuAAC reaction also led to the formation of copper nanoparticles 
(CuNPs) of diameter ca. 100 nm and of narrow size distribution, presumably from the CuAAC 
catalyst, as evidenced by the surface plasmon resonance bands probed by UV/Vis spectroscopy 
(Figure 4.3), the inorganic residue left after thermogravimetric analysis (Figure 4.4), TEM 
images (Figure 4.5) and DLS measurements (Figures A.12-A.27). The formation of CuNPs 
from the reduction of Cu
2+
 upon microwave irradiation has been reported before, and recent 
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work has suggested that well defined particles such as those obtained in our work require the 
presence of a surfactant to template their growth.
[213-215] 
Considering our system, this suggests 
that the peptide polymer conjugates act as a surface active agent to promote the formation of 
CuNPs. The nanoparticles were removed by oxidation of Cu
0
 and Cu
1+
 to Cu
2+
 by the reduction 
of I2 to I
-
, followed by washing with EDTA, sodium thiosulfate and water. 
 
 
Scheme 4.1: Synthetic strategy for the formation of (N-methylated cyclic peptide)-polymer conjugates. 
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Figure 4.3: UV/Vis absorption spectrum of di
NMe
CP1-pBA22 in THF (0.31 mM) before I2 treatment. The 
absorption peaks labelled correspond to the plasmon resonance bands of CuNPs. 
 
 
 
Figure 4.4: TGA profile of di
NMe
CP1-pBA22 sample before I2 treatment. 
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Figure 4.5: TEM of di
NMe
CP1-pBA22 before I2 treatment. Prepared with 2 drops from THF solution 
(0.2 mM) onto grid. 
 
The formation of dimers from the monotopic conjugates was investigated by focusing on 
conjugates 
NMe
CP1-pBA16 and 
NMe
CP1-pBA30. The formation of dimers from conjugate 
NMe
CP1-pBA16 was initially evidenced by 
1
H NMR spectroscopy, which showed a clear shift in 
signal for the NH protons involved in H-bonding (Figure 4.6). In addition, SEC analyses using 
THF as the eluent of 
NMe
CP1-pBA16 revealed an elution peak at about twice the peak molecular 
weight of the polymer, whilst analyses in DMF + LiBr (0.1 %wt) eluent, which is expected to 
disrupt hydrogen bonds, shows a symmetrical elution profile close to that of the alkyne-bearing 
polymer, which we attribute to the disassembled conjugate (Figures 4.7 and 4.8). Conjugate 
NMe
CP1-pBA30, on the other hand, was not observed to form dimers in THF by SEC (Figure 
4.9), thus suggesting that the length of the conjugated polymeric chain can affect the assembly. 
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Figure 4.6: 
1
H NMR of 
NMe
CP1-pBA16 in CDCl3+TMS. δ 8.35-8.80 ppm assigned to NHdimer, present in 
the conjugate. 
 
 
Figure 4.7: Size exclusion chromatogram of 
NMe
CP1, pBA16 and 
NMe
CP1-pBA16 in THF + hydroquinone 
(0.05 %wt). The shift in peak molecular weight (Mp) of 
NMe
CP1 and 
NMe
CP1-pBA16, as well as the 
asymmetric tailing of the elution profile towards lower molecular weights, demonstrate the self assembly 
into dimeric species in solution. Molecular weights have been calibrated with polystyrene standards with 
toluene (0.5 %vol) used as a flow rate marker. 
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Figure 4.8: Size exclusion chromatogram of 
NMe
CP1, pBA16-alkyne and 
NMe
CP1-pBA16 in DMF + LiBr 
(0.1 %wt) + hydroquinone (0.05 %wt). The ‘lack of shift’ in peak molecular weight (Mp) of 
NMe
CP1 and 
NMe
CP1-pBA16, as well as the symmetric tailing of the elution profile, shows the species are in a 
disassembled state. Molecular weights have been calibrated with polystyrene standards with water 
(1.15 %wt) used as a flow rate marker. 
 
 
Figure 4.9: Size exclusion chromatogram of pBA30-alkyne and 
NMe
CP-pBA30 in THF + hydroquinone 
(0.05 %wt). The relatively small shift in peak molecular weight and symmetrical elution profile suggests 
a lack of dimerisation. Molecular weight calibrated with polystyrene standards and toluene (0.5 %vol) 
was used as a flow rate marker. 
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ATR-FTIR also confirmed the presence of H-bonding (Figure 4.10, full spectra Figure 4.11) 
of conjugate 
NMe
CP1-pBA16. A shift was observed in local absorption maximum to 1244 cm
-1
, in 
the region expected for a β-sheet structure, with a broad shoulder extending to 1290 cm-1, which 
is characteristic of the random coil structure of the polymer.
[216] 
Interestingly, the discrepancy 
with the β-sheet absorption of NMeCP1 (1217 cm-1) could signify the effect of a long chain 
covalently attached to β-sheet sites. A closer look at the Amide I mode also shows a shift in the 
absorption maximum, between the peptide 
NMe
CP1 (1622 cm
-1
) to the conjugate 
NMe
CP1-pBA16 
(1628 cm
-1
) indicative of the peptides response to the polymeric environment.
[217]
 Furthermore, 
we also observe absorption in the range 1670-1695 cm
-1
, which is generally attributed to 
antiparallel β-sheet structures.[216] 
 
 
Figure 4.10: ATR-FTIR spectra of 
NMe
CP1 and 
NMe
CP1-pBA16 cast as a film from a chloroform solution. 
Labelled peaks: pBA C=O stretch (1732 cm
-1
), antiparallel β-sheet (1682 cm-1), peptide C=O stretch 
(Amide I, 1622 and 1628 cm
-1
), β-sheet/random-coil (Amide III, 1244 cm-1), β-sheet (Amide III, 
1217 cm
-1
). These modes match the expectation from self assembling cyclic peptides. 
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Figure 4.11: Full ATR-FTIR spectra of 
NMe
CP1 and conjugates. Control refers to the product of the 
conjugation reaction of the 
NMe
CP1 without polymer. All samples were casted as a film from a 
chloroform solution. 
 
Conjugates 
NMe
CP1-pBA16 and 
NMe
CP1-pBA30 were also analysed by light scattering in 
THF and CHCl3 solutions. To our surprise, dynamic light scattering (DLS) analyses of 
NMe
CP1-pBA16 at room temperature revealed large structures that disappear upon increase in 
temperature and decrease in concentration, suggesting possible aggregation (Figures A.12-
A.14). DLS analyses of conjugate 
NMe
CP1-pBA30 (after the removal of copper), however, did 
not reveal such structures (Figure A.16), suggesting that the aggregation mechanism is also 
dependent on the length of the pBA chain. In order to investigate the impact of the polymer 
functionality, a peptide-poly(styrene) (pSty20-alkyne; Mn 2400 g·mol
-1
, DP 20, Đ 1.15) 
conjugate, 
NMe
CP1-pSty20, was synthesised following the procedure described above. SEC in 
THF eluent confirmed formation of dimers (Figure 4.12), and DLS analyses in CHCl3 and THF 
(Figures A.17-A.22) reveal the formation of large structures (Figures A.21 and A.22; after 
copper is removed). Aggregation in large structures in solution seems therefore to be dependent 
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Figure 4.12: Size exclusion chromatogram of pSty20-alkyne and 
NMe
CP1-pSty20 in THF + hydroquinone 
(0.05 %wt). Molecular weights calibrated with polystyrene standards and toluene (0.5 %vol) was used as 
a flow rate marker. Excess polymer was not removed. 
 
 
Figure 4.13: TEM of 
NMe
CP1-pSty20 before I2 treatment. Prepared with 2 drops from THF solution 
(1.1 mM) onto grid. TEM post-I2 treatment shows none of such structures. 
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on the formation of dimers, although the nature of the aggregates seems dependent on the 
functionality of the polymeric chain. Interestingly, ill-defined CuNPs (Figure 4.13) were 
generated by the conjugation of pSty as compared to well-defined CuNPs (Figure 4.5) from the 
conjugation of pBA which correlates well with the idea of conjugates possessing surface active 
properties which facilitate the formation of CuNPs. 
4.4 Ditopic assembly 
Having established the ability of the self-complementary peptidic units to drive the assembly 
of a conjugate via H-bonds, we turn our attention to ditopic conjugate di
NMe
CP1-pBA22, a 
homotelechelic polymer with α,ω-peptide termini, to be used as the base of a supramolecular 
polymer. Initial attempts to characterise assemblies of di
NMe
CP1-pBA22 by size exclusion 
chromatography (SEC) in THF and DMF + LiBr (0.1 wt%) resulted in only very weak signals 
corresponding to the elution time of 
NMe
CP1 and the polymer pBA22-dialkyne, suggesting that 
the self assembled product of di
NMe
CP1-pBA22 is of very large size and is filtered by the guard 
column of the instrument, leaving only unreacted starting materials in the eluted sample. DLS 
analyses of the sample in THF revealed the presence of large structures, as observed for the other 
conjugates (Figures A.23-A.27). These structures were analysed in THF by static light scattering 
(SLS), and a Berry plot
[218,219]
 was constructed to extrapolate a weight average molecular weight 
(Mw) of (3±1) × 10
7
 g·mol
-1 
for the assembly formed from di
NMe
CP1-pBA22 (see Figure 4.14). 
This calculated Mw (corresponding to a degree of polymerization of ca. 1400) is unexpectedly 
large for an isodesmic supramolecular polymer with Ka~1700 M
-1
 (ca. DP 5 would be expected 
in a less H-bonding competitive solvent such as CDCl3 at 2 mM, according to the measured Ka by 
1
H NMR).
[220]
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Figure 4.14: Berry plot of di
NMe
CP1-pBA22 in THF. 15-115° increments of 5°. Double extrapolation 
yielded: Mw (3±1) × 10
7
 Da, Rg 250±10 nm, A2 (4.6±0.2) × 10
-6 
cm
3
.mol.g
-2
. 
 
DLS was utilised to probe further the nature of the structure obtained from di
NMe
CP1-pBA22 
in THF and in CHCl3, by following the response with changes in concentration, solvent 
composition and heat. In these studies, the CuNPs were kept in the sample and used as an 
internal reference. In an isodesmic assembly, decreasing concentration should lead to smaller 
aggregates as the probability for H-bonding groups to find each other is lowered. In our system, 
we observed no decrease in size upon dilution to 10 mg/mL, 1 mg/mL and 0.05 mg/mL in both 
THF and CHCl3 (Figures A.23-A.24). Finally, 0, 1, 2 and 20 equivalents of 
NMe
CP1 and 
NMe
CP1-pBA16 were added to a solution of di
NMe
CP1-pBA22. The doping of monotopic species 
in supramolecular polymers have been found to greatly impact the physical properties of the 
system by acting as “chain stoppers”.[221-232] Light scattering revealed that, even in the presence 
of 20 molar excess of monotopic species, the structure remained intact, thus confirming the 
product is not obtained from the isodesmic association of di
NMe
CP1-pBA22 (Figures 4.15 and 
4.16; CuNPs were removed from 
NMe
CP1-pBA16 but kept in the samples of di
NMe
CP1-pBA22 as 
internal reference for size and intensity). Furthermore, analysis of 
NMe
CP1-pBA16 alone by SLS 
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in THF and construction of a Berry plot revealed an assembly with Mw of (4±1) × 10
7
 g·mol
-1 
(Figure 4.17), thus suggesting that the monotopic species also assembles in large aggregates, an 
observation far from being intuitive. 
 
 
Figure 4.15: Addition of monotopic species 
NMe
CP1 to ditopic species di
NMe
CP1-pBA22 in THF. To 
reach thermodynamic equilibrium, samples were heated to 40 °C for at least 20 minutes and cooled to 
20 °C before acquisition. The additive led to no change to distribution. 
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Figure 4.16: Addition of monotopic species 
NMe
CP1-pBA16 (post-I2 treatment) to ditopic species 
di
NMe
CP1-pBA22 in THF. To reach thermodynamic equilibrium, samples were heated to 40 °C for at least 
20 minutes and cooled to 20 °C before acquisition. The additive led to no change to distribution, arguably 
an increase in size distribution spread. 
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Figure 4.17: Berry plot of 
NMe
CP1-pBA16 in THF. 25-115° increments of 5°. Double extrapolation 
yielded: Mw (4±1) × 10
7
 Da, Rg 200±5 nm, A2 (3.0±0.3) × 10
-6 
cm
3
.mol.g
-2
. 
4.5 Structural interpretation 
In an attempt to understand the mechanism of formation of the large structures observed by 
light scattering, we turned our attention to small angle scattering techniques. When examining 
the SLS data of 
NMe
CP1-pBA16 and di
NMe
CP1-pBA22 using an I-q plot on a log-log scale 
(Figure 4.18), we observe a change in the intensity with angle, which suggests large structures 
that are an appreciable size compared to the wavelength of visible light. Notably a peak in 
scattered intensity at low q (instead of plateauing in approach to the Guinier regime) suggests 
particle-particle interactions that decrease with dilution but are still observed at concentrations 
that approach the detection limits (2 mg/mL). With inter-particle interactions at these dilute 
conditions we conceive that the assemblage is probably a highly extended structure which would 
explain the broad size distribution obtained from the DLS results. To probe the intermediate 
regime, small angle neutron scattering (SANS) was carried out on the conjugates to obtain intra-
particle scattering information (i.e. form factor, see Figures A.28-A.32). Firstly, a steep I α q-2 
relationship (a power law of q
-2
 is typically associated with the geometry of disks or Gaussian 
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polymer chains) was found at q < 0.01 Å for 
NMe
CP1-pBA16 and q < 0.03 Å for 
di
NMe
CP1-pBA22. This crudely matches the relationship found at the large angles of the SLS 
data (Figure 4.19) supporting the observation that the size of the structures formed is 
comparable to the wavelength of light. At q > 0.01 Å for 
NMe
CP1-pBA16 and q > 0.03 Å for 
di
NMe
CP1-pBA22, scattering indicates an additional layer of structure in the length scales of 
Ångstroms to nanometers. 
 
 
 
Figure 4.18: SLS data on 
NMe
CP1-pBA16 (top) and di
NMe
CP1-pBA22 (bottom). Relative intensities 
normalised by concentration. 
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Figure 4.19: Small angle scattering data of 
NMe
CP1-pBA16 (2 mM, 4 mM) and di
NMe
CP1-pBA22 (2 mM) 
in THF or THF-d8. Incoherent background scattering has been subtracted off SANS data and the intensity 
of the SLS data has been offset to match the corresponding SANS data. 
 
To investigate the origin of the small scale structure, we carried out SANS on the 
unconjugated N-methylated cyclic peptide 
NMe
CP1 which showed scattering over the probed 
q-range. A uniform cylinder with fixed dimensions, based on the unit cell from 
crystallography
[39]
 to model a dimer (radius 5 Å, length 10.2 Å), was insufficient to describe the 
scattering observed (Figures A.34-A.36).
[150]
 Permitting changes to the dimensions and using 
simpler geometries (uniform spheres, uniform ellipsoids) provided better fits to the data when 
the overall volume of the shape was larger than that of a dimer (Figures 4.20). These volumes 
trend upwards with increasing concentration and elongation is especially apparent in the 4 mM 
sample (Figures 4.20). This result suggests that two or more N-methylated cyclic peptides are 
capable of assembling/aggregating in THF-d8, despite their intended design, and implicates that 
the end-groups of the conjugates are similarly able to associate. 
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 1 mM 2 mM 4 mM 
Scale 0.00996
†
 0.0199
† 0.0398† 
Radiusa (rotation axis) (Å) 9 23 33 
Radiusb (Å) - 6.6 4.3 
SLD sphere/ellipsoid (× 10
-6
 Å
-2
) 4.30
†
 4.30
†
 4.30† 
SLD solvent (× 10
-6
 Å
-2
) 6.35
†
 6.35
† 6.35† 
Incoherent background (cm
-1
) 0.0685
†
 0.0720
† 0.0718† 
Figure 4.20: Fitting uniform sphere model to 
NMe
CP1 (1 mM) and uniform (needle-like) ellipsoid model 
to 
NMe
CP1 (2 mM, 4 mM). (
† = held parameter value) 
 
Collating our observations, we suggest that in THF the ditopic species assemble and adopt a 
large (~400 nm) and extended structure (from SLS) resembling a Gaussian polymer (from SLS 
and SANS) where the cyclic peptide end-groups segregate into local (~1 nm) domains (from 
SANS) creating unspecific, non-covalent branch points in the structure. In the case of the 
monotopic species, the cyclic peptide aggregation into ~1 nm domains leads to smaller 
assemblies consisting of a cyclic peptide core surrounded by a polymeric chain corona, and 
aggregation of these assemblies leads to much larger structures, as evidenced by the increase in 
scattering intensity upon increase in conjugate concentration. H-bonding takes place (from 
ATR-FTIR, NMR and SEC analyses) but its role is unclear; it can be imagined that either 
directed dimer formation or undirected H-bonding facilitates the segregation of the cyclic 
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peptides; alternatively H-bonding has been acting as a qualitative probe for the proximity of 
cyclic peptide end-groups. In summary, whilst H-bonds between two cyclic peptides does occur 
and lead to the formation of dimers, a second interaction between cyclic peptides lead to the 
formation of small peptide domains that act as physical crosslinking points and lead to the 
formation of large polymeric structures. This interpretation is similar to the accounts of lateral 
aggregation in the use of quadruple hydrogen bonding unit, ureidopyrimidinone,
[221]
 as end-
groups.
[233-235]
 Sijbesma et al. has attributed the behaviour to the combination of microphase 
separation and π-π stacking, which is moreover amplified by the introduction of urea or urethane 
groups in the conjugation process.
[235]
 
In order to further probe the formation of smaller domains from the aggregation of peptides 
within the polymer structure, we analysed the conjugates by differential scanning calorimetry 
(DSC). DSC traces (Figure 4.21) reveal that two distinct phase transitions exist for 
NMe
CP1-pBA16 and di
NMe
CP1-pBA22, the first occurring around -50 
o
C, and is characteristic of 
the glass transition of pBA chains, and the second occurring around 50 
o
C. The second transition 
agrees with our light and neutron scattering characterisation, and the formation of small domains, 
presumably driven by the aggregation of the cyclic peptide. Conjugate 
NMe
CP1-pBA30 and 
NMe
CP1-pSty20, on the other hand, only exhibit a transition corresponding to the polymeric 
chain, -50 
o
C (pBA) and 100 
o
C (pSty), respectively. The lack of the second transition in 
NMe
CP1-pBA30 coincides well with the lack of assembly and H-bonding observed from 
conjugate, likely due to the polymer shielding the peptide end-groups. PSty is a solid where we 
would expect to see the transition due to the aggregation of the cyclic peptide, as a result it is 
difficult to compare and interpret the DSC trace of 
NMe
CP1-pSty20. 
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Figure 4.21: DSC traces of peptides, polymers and conjugates (all in bulk) presented in this chapter. 
Heating at 10 °C/min. 
4.6 Chapter conclusion 
In conclusion, we have shown the unexpected assembly of (N-methylated cyclic peptide)-
polymer conjugates into large aggregates by a combination of H-bonds and physical aggregation 
of the cyclic peptides into small domains. The conjugates assemble and adopt a large (~400 nm) 
and extended structure (resembling a Gaussian polymer), in which the cyclic peptides aggregate 
into small (~1 nm) domains, creating physical branch points in the structure. Varying the length 
and/or chemical functionality of the attached synthetic polymer was found to impact the 
assembly in such structures. 
Having established the assembly characteristics of (N-methylated cyclic peptide)-polymer 
conjugates, we were now interested by their behaviour in the presence of nanotube forming 
conjugates. This would test the capability of ‘capping’ the nanotubes to add tube-end 
functionality and control the tube length. 
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5 ‘Capped’ nanotubes 
5.1 Introduction 
In an attempt to gain better control over the assembly length, we have employed and studied 
partially N-methylated cyclic peptides (
NMe
CPs) which are engineered to have directed 
H-bonding restricted to one face. It has been found that N-functionalised cyclic peptides and CPs 
can associate together as evidenced by previous work by Ghadiri et al. where monotopic cyclic 
peptides were used to modulate the flux of ions through cyclic peptide based channels (Scheme 
5.1).
[66]
 
 
 
Scheme 5.1: Illustrating the use of N-functionalised cyclic peptides 2 and 3 to modulate the flux of ions 
through cyclic peptide channels, self assembled in a lipid bilayer. Adapted from Ghadiri et al.
[66]
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We envisaged that in a binary mixture of 
NMe
CP species and CP species, the 
NMe
CP species 
would present itself at the ends of the nanotube assembly to behave as ‘chain stoppers’.[229] This 
follows from early work done by Meijer et al. who observed a significant reduction in viscosity 
by the addition of monotopic chain stoppers in supramolecular polymers.
[221-223]
 Lehn et al. 
observed the impact of monotopic species in a heterocomplementary H-bonding supramolecular 
system.
[224]
 Soon after, Bouteiller et al. and Knoben et al. used monotopic monomers in 
conjunction with heterocomplementary ditopic monomers to establish the use of chain stoppers 
as a means to block the concentration dependence of the chain length, using rheological and light 
scattering measurements to support the theoretical model they had developed.
[227,228,231,232]
 In 
more recent work, Smulders and Meijer et al. investigated the chain stopper effect on the 
cooperatively self assembling motif of benzene-1,3,5-tricarboxamide (Scheme 5.2), applying 
mathematical and computational models to viscometry data.
[230]
 
 
 
Scheme 5.2: Molecular structure of ditopic 1 and monotopic 2 used and a representation of the resulting 
cooperative self assembly. Adapted from Smulders and Meijer et al.
[230] 
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5.2 Chapter aim 
This chapter explores the feasibility of using partially N-methylated cyclic peptides, and 
polymer conjugate derivatives, as chain stoppers to control the length of assembly and the 
functionality at the ends of nanotubes. Based on the synthesised compounds and findings from 
the previous chapters of this thesis, we observe by small angle neutron scattering, the assembly 
that results when CPs and 
NMe
CPs are mixed. Part of this study includes the setup of a 
thermodynamic dynamic model to gain theoretical insight into this scheme. 
5.3 Mixing experiments 
In Chapter 4, we investigated cyclo[-L-Lys(N3)-D-Phe-(N-Me-L-Ala-D-Phe-)3] 
NMe
CP1, and 
conjugates
 NMe
CP1-pBA16 and 
NMe
CP1-pSty20, for which we observed H-bonding and 
dimerisation, despite their propensity to aggregate in solution beyond the directional antiparallel 
β-sheet motif (forming large (400 nm) extended structures in the case of the conjugates). By 
small angle neutron scattering, we observed the scattering profiles of mixtures of 
NMe
CP1, 
NMe
CP1-pBA16 and 
NMe
CP1-pSty20 with CP1-(p(BA-d9)29)2 conjugates in THF-d8 in molar 
ratios of 1:1, 1:2, 1:4 ([CP]:[
NMe
CP]) keeping the concentration of the ditopic species constant at 
1 mM. Due to the formation of large structures by the 
NMe
CP conjugates, it was necessary to 
manipulate the data to filter the contribution of scattering in order to probe the nanotube 
assembly. Subtracting the scattering intensities of the control experiments (
NMe
CP species and 
with no CP conjugates in THF-d8) was a straightforward manipulation that yielded a reasonable 
set of data to interpret. The resulting scattering profiles (Figure 5.1) showed no change to the 
geometry of the nanotube assembly. This result is particularly interesting given the several 
accounts in literature showing a decrease in chain length with the addition of monotopic 
species.
[221-232]
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Figure 5.1: SANS profiles of binary mixtures of 
NMe
CP1, 
NMe
CP1-pBA16 and 
NMe
CP1-pSty20 with 
CP1-(p(BA-d9)29)2 conjugates in THF-d8 in molar ratios of 1:1, 1:2, 1:4 ([CP]:[
NMe
CP]) keeping the 
ditopic concentration constant at 1 mM. Profiles shown is after subtraction of the scattering intensities of 
the control experiments (
NMe
CP species and with no CP conjugates in THF-d8). 
 
5.4 Thermodynamic treatment 
To gain insight to the inconsistency between the lack of change we have observed and the 
literature accounts of chain stopping,
[221-231]
 we turn to consider the thermodynamics for 
supramolecular polymers. Knoben et al. express the equilibrium constant K of associating units 
as a function of the concentration of bonds and free binding groups of an isodesmic 
assembly.
[228]
 They then further introduce the effect of monotopic species on the number average 
degree of polymerisation of a supramolecular polymer assembled from ditopic monomers. The 
treatment is established from the assumption that the addition of n amount of monotopic 
monomer initiates one chain, which is used to redistribute the ditopic monomers to give the 
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number average degree of polymerisation <DP(x)>n as a function of the fraction of chain 
stoppers x. This model unfortunately does not take into consideration the equilibrium of 
monotopic monomers adding to ditopic monomers, and further does not consider the equilibria 
of two monotopic monomers associating to one assembly (i.e. ‘capped’ at both ends of the 
assemblies) or to another monotopic monomer (i.e. dimerisation) which are situations that cannot 
be neglected in our system. To address this, we expand from the model of Moore et al. who have 
treated the growth of both isodesmic and cooperative supramolecular polymers by expressing the 
equilibrium as a combination of the preceding monomer additions (for simplicity, we consider 
only the isodesmic case; Sub-chapter A.3 describes our theoretical treatment in more detail):
[196] 
 
[  ]  [ ]
 ∏   
 
   
     [  ]
  (5.1) 
 
Where [Ai] is the concentration of ditopic assembly consisting of i ditopic units, [A] is the 
concentration ditopic unit in its monomeric form, Ki is the equilibrium constant of the addition of 
i ditopic units. With this, the number average degree of polymerisation <DP>n can be 
calculated:
[196]
 
 〈  〉  
 
   [ ]
 (5.2) 
 
Now we consider the addition of monotopic species B which can interact with A and/or 
another unit of B, then we have the following: 
 [  ]      [ ]
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 [   ]    [  ][ ] (5.4) 
 [    ]    
 [  ][ ]
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Scheme 5.3: Graphical representation of the inventory of materials and definition of assemblies. Blue 
squares labelled ‘A’ represent a ditopic unit; rounded squares labelled ‘B’ represent monotopic units 
where unpatterned this represents monotopic units associated to ditopic units, and where cross-patterned 
represents monotopic units in monomeric form or in a dimer with another monotopic unit. 
 
Where [B] and [BB] is the concentration of unimers and dimers of monotopic species with an 
association constant Kdim, and [AiB] and [BAiB] is the concentration of one and two monotopic 
species associating with Ai with equilibrium constant KB. 
Now we establish the inventory of materials and define the assemblies, as illustrated in 
Scheme 5.3. 
The number average degree of polymerisation <DP>n is given by: 
 
〈  〉  
     
  
 (5.6) 
 
Where AT and BT is the total concentration of A and B, respectively; and NT is the number of 
assemblies (i.e. nanotubes): 
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It is also useful to solve for the number distribution of ditopic species <A>n-A only which 
intentionally neglects B and BB as nanotubes: 
 
〈 〉         
  
       
 
  
∑ [  ]
 
    ∑ [   ]
 
    ∑ [    ]
 
   
 
 
    [ ] 
 (5.10) 
 
This exclusion allows us to probe the effect of adding B on the assembly of A, rather than 
simply skewing the average degree of polymerisation towards monomeric and dimeric forms of 
B. Similarly by selecting our definitions, we calculate the number distribution of monotopic 
species unassociated with ditopic species, given as <B>n-B free: 
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 (5.11) 
 
Solving for [A] numerically, we plot <DP>n, <A>n-A only, <B>n-B free as a function of AT, 
where K = KB = Kdim and varying the mole fraction of BT (Figures 5.2-5.4): 
 
 
Figure 5.2: Number average degree of polymerisation <DP>n  as a function of ditopic concentration AT 
with ratios of monotopic species B: 0 %,
[196]
 0.1 %, 10 %, 50 %, and 80 %. 
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Figure 5.3: Number average degree of polymerisation of nanotubes consisting of ditopic monomers 
<A>n-A only  as a function of ditopic concentration AT with ratios of monotopic species B: 0.1 %, 10 %, 
50 %, and 80 %. 
 
 
 
Figure 5.4: Number average degree of polymerisation of only monotopic monomers <B>n-B free as a 
function of ditopic concentration AT with ratios of monotopic species B: 0.1 %, 10 %, 50 %, and 80 %. 
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It is clear from Figure 5.2 that <DP>n is expected to decrease with the addition of monotopic 
species; the effect is more prominent at higher concentrations of AT but still noticeable at the 
concentrations we have studied experimentally (1.0 mM). We have also established from Figure 
5.3 that the assembly of A is decreasing by the addition of monotopic species; this is expected 
due to the dependency of [A] on KB and [B] (and therefore BT) which is described by equation 
(5.7). This influence is further established by removing the association between A and B. 
Analytically, as KB   0, (5.7) reverts to the same solution without the addition of B units, 
resulting in an unperturbed value of <A>n-A only; numerically, this has been shown by setting 
KB = 0.001 M
-1
 in Figure 5.5. It should also be noted, in the case where KB = 0.001 M
-1
, that 
<DP>n has dropped to values similar to when KB = K, reflecting the influence of [B] and [BB] in 
statistically skewing <DP>n. Care should therefore be taken before concluding that ‘chain 
stopping’ is taking place when interpreting experimental data of <DP>n. A related and intuitive 
observation is also noteworthy: if KB is high relative to K, monotopic species strongly interact 
with ditopic species to reduce <A>n-A only (Figure 5.6); whereas, if Kdim/KB is high, the unimeric 
(and available for binding) concentration of monotopic species is low, minimising the impact to 
<A>n-A only (Figure 5.6). 
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Figure 5.5: <DP>n and <A>n-A only as a function of AT, with and without substantial interactions between 
monotopic and ditopic species.  
 
 
 
Figure 5.6: <DP>n and <A>n-A only as a function of AT with high dimerisation between monotopic species, 
varying the interactions between monotopic and ditopic species. It should be noted that the situation 
where K = Kdim = 2000 M
-1
; KB = 4×10
9
 M
-1
 is represented identically by the black curves. 
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At this point we can propose several explanations as to why SANS did not reveal a change in 
structure even at 1:4 ([CP]/[
NMe
CP], 80 % monotopic species): 
1/ The simplicity of our model, it has already been hypothesised that the nanotube growth is 
cooperative in nature whilst we have modelled the system with the isodesmic growth of ditopic 
units. Such an explanation would be interesting to further explore as a possibility to exploit 
monotopic cyclic peptides to introduce functionality to ends of long nanotubes, as compared to 
an isodesmic system where the degree of polymerisation would be decreased significantly. The 
study on the end functionalisation of isodesmic assemblies using the developed model can be 
found in Sub-chapter A.3. 
2/ Alternatively, our derivation of number averages in the theoretical treatment might be 
inaccurate when compared to our weighted average data from SANS. 
3/ The lack of ‘chain stopping’ could also be explained by the lateral aggregation of NMeCPs 
that we observed in Chapter 4. This might be crudely resembled by the description of 
Kdim > K = KB in our model, i.e. reducing the availability of monotopic species that are able to 
bind to ditopic species (Figure 5.6) which shows the imperturbation of <A>n-A only from the case 
with no monotopic species, but does show the decreases in <DP>n by statistically skewing the 
distribution to dimers. 
Given that previously studied cooperative systems have been the subject of chain stopping at 
significantly lower concentrations and fractions of the monotopic species,
[227,228,230-232]
 and 
furthermore also explored through the use of light scattering techniques,
[227,228]
 we rationalise 
that the first two points are unlikely to sufficiently explain the observation of no change to our 
assembly. The third explanation is more reasonable and suggests that 
NMe
CP1 is an inefficient 
chain stopper for CP1. 
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5.5 Chapter conclusion 
Chain stopper experiments were carried out using N-methylated cyclic peptide motifs as 
monotopic species to nanotube forming cyclic peptides. Small angle neutron scattering 
experiments showed a lack of change in the nanotube assembly even when the sample comprised 
of 80 % monotopic species. We developed a thermodynamic model to treat the influence of 
monotopic species on the otherwise isodesmic assembly of ditopic species. While this model was 
used to gain insight into the inconsistency between our experimental data and literature accounts 
of chain stopping, the model ultimately predicted a significant decrease in degree of 
polymerisation at the concentrations we experimentally tested. We have attributed the unusual 
behaviour of our supramolecular system to the lateral aggregation of 
NMe
CP1 that we observed in 
Chapter 4. The decreased availability of 
NMe
CP1 in monomeric form explains the inefficiency as 
a chain stopper. 
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6 Conclusions and outlook 
The self assembly of (cyclic peptide)-polymer conjugates was explored as a supramolecular 
approach towards engineering complex nanostructures. The solubility imparted by the tethered 
polymers permitted the direct characterisation of the nanotube assembly in solution through the 
use of small angle neutron scattering (SANS). Astonishingly, the influence of the tethered 
polymer on the self assembly of the cyclic peptide not only stabilised the assemblies of 
nanotubes, preventing lateral aggregation, but also shielding the cyclic peptide from complete 
disassembly in a highly H-bonding competitive solvent (trifluoroacetic acid (TFA)). 
Nevertheless in less H-bonding competitive solvents (chloroform, tetrahydrofuran), non-
aggregated nanotubes with high aspect ratios could be obtained. The conjugate susceptibility to 
the addition of TFA was also found to depend on the polymer solvation, returning back to the 
shielding quality of the polymeric sheath, where a well-solvated polymer permitted more 
disruption to the assembly. To further our study, we synthesised and conjugated two additional 
cyclic peptides, varying by the substitution of Trp to either Lys(Boc) or Lys residues. Not only 
are these cyclic peptides potentially useful for functionalising and/or crosslinking the immediate 
shell of the nanotube for future applications, but both also observably altered the self assembled 
structure, where solubility and/or lateral aggregation were influenced by the functional groups 
from the peptide residue. 
In expanding the versatility of these conjugates to synthesise nanostructures, a study was 
made on partially N-methylated (cyclic peptide)-polymer conjugates. 
NMe
CPs and derivative 
conjugates were shown, by size exclusion chromatography, to be able to dimerise. However 
under closer inspection by differential scanning calorimetry, light and neutron scattering, further 
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aggregation beyond the dimerisation of 
NMe
CPs was detected. In the case of the 
NMe
CP-polymer 
conjugates, this unspecific aggregation resulted in large (~400 nm) extended structures with 
small (~1 nm) domains. 
Binary mixtures of 
NMe
CP species and nanotube forming CP species were prepared and 
analysed by SANS, pursuing the vision of adding functionality to the ends of nanotubes and 
better control over the length of the assembly. No change to the assembly was observed with 
ratios of 1:1, 1:2 and 1:4 ([CP]/[
NMe
CP]). A theoretical model was developed to consider the 
thermodynamics of mixing monotopic and ditopic species but was unable to explain the unusual 
behaviour of our system. Proposing several explanations, we concluded the biggest contributor 
towards the lack of chain stopping is due to the aggregation of 
NMe
CPs, significantly decreasing 
the available monotopic species to bind with ditopic CPs, and reducing its effectiveness as chain 
stoppers. 
Recent work by Bouteiller et al. described a simple and effective chain stopping system, by 
using anions to bind to NH groups.
[236]
 Removing the need to design a complementary moiety to 
reduce chain length, this is an ideal experiment to test the possibility of the reducing length of 
the nanotubes by chain stopping. While we have used lithium bromide to demonstrate the ability 
to remove the H-bonding of 
NMe
CPs (Sub-chapter 4.3), a recent study by Byrne et al. have used 
the long chained imidazolium based ionic liquid (1-octyl-3-methylimidazolium chloride) with 
the addition of water (15 wt%) to induce the alignment of cyclic peptide nanotubes,
[97]
 
suggesting that there may be a feature of the assembly mechanism of CPs that resists chain 
stopping. 
The use of charged monotopic cyclic peptides is another alternative design that may offer a 
unique approach to chain stopping, which may be more interesting for the sake of end-group 
functionality. The use of formally charged monotopic species could remove the lateral 
aggregation as well as remove self association (i.e. a low Kdim) by Coulombic repulsion. This 
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would be an ideal candidate for mixing with neutral nanotubes in an attempt to observe chain 
stopping. Furthermore, one could envisage that the long range repulsion of these monotopic 
species may result in a reduced efficacy as chain stoppers as the nanotube length shortens 
(reducing the proximity of the tube ends), and potentially providing a means towards tuning the 
chain stopping effect by Coulombic strength. It also suggests that both ends of the nanotubes 
could be functionalised, as opposed to the current systems with neutral chain stoppers which rely 
solely on statistics to determine the degree of functionality at the chain ends. Ghadiri et al.
 [66]
 
have already shown that from an application point of view, the charged ‘caps’ can also serve to 
modulate specificity in the access to the internal channel. 
While (cyclic peptide)-polymer conjugates have proven to be a versatile motif to synthesise 
nanostructures, embracing more exotic cyclic peptide designs is key to unlocking more 
sophisticated applications that exploit the sub-nanometer internal channels that are unique to the 
system. The majority of the polymer conjugates use alt(D,L)-α-CPs, with exception of Xu et al. 
who substituted one residue, in an otherwise all α-CP, for a γ-residue; a unique approach to 
compensating for the additional synthetic complexity of γ-CPs.[63] Adopting γ-residues are 
particularly enticing due to greater range of internal diameters available for the nanotubes. The 
marriage of γ-CPs/(α,γ)-CPs and polymers would be a synergistic relationship since without the 
steric stabilisation, there is a propensity for nanotubes to laterally aggregate, forming barrel and 
stave channels which reduces its usefulness as a pore with sub-nanometer control over the size. 
Further, adding functional groups to the internal pore (by the γ-residues) opens the system to be 
engineered for modulating molecular channels, encapsulating guests for drug delivery or for 
catalysis. In combination, control over the orientation of these highly anisotropic structures will 
be a significant step in the development of future applications, with opportunities in templating 
to obtain nanowires or optical devices. The microphase separation of polymers has already been 
shown to be a simple route to control the orientation and was used as a sub-nanometer porous 
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film.
[122]
 Alternatively, tethering cyclic peptides through the N-functionalised face to a surface 
could provide an ideal method to seed nanotubes to grow vertically from a surface. 
The use of (cyclic peptide)-polymer conjugates is a truly versatile system as a 
supramolecular approach to synthesising nanostructures with complex architectures. We have 
presented fundamental studies in the self assembly behaviour of (cyclic peptide)-conjugates to 
aid the future development towards the precise engineering of nanostructures. While this opens 
exciting possibilities for applications that may utilise the complex structures, we also hope the 
study of self assembly for synthetic compounds may act as a model and bring insight to natural 
systems involving β-sheet association and peptide/protein aggregation. 
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Appendix 
A.1 Chapter 3 – (Cyclic peptide)-polymer conjugate nanotubes 
 
 
 CP1 (1 mM) in 
DMSO-d6 
CP1 (2 mM) in 
DMSO-d6 
CP1 (4 mM) in 
DMSO-d6 
Scale 0.00125† 0.0025† 0.005† 
Ra (rotation axis) (Å) 23.6822 23.1123 22.5993 
Rb (Å) 135.578 130.37 128.576 
SLD ellipsoid (×10
-6
 Å
-2
) 2.81 3.13 3.14 
SLD solvent (×10
-6
 Å
-2
) 5.28† 5.28† 5.28† 
Incoherent background (cm
-1
) 0.0498† 0.0477† 0.0479† 
Figure A.1: Uniform ellipsoid model fits to CP1 in DMSO-d6
 
(
†
=held parameter value) 
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 CP1 (1 mM) in 
DMSO-d6 
CP1 (2 mM) in 
DMSO-d6 
CP1 (4 mM) in 
DMSO-d6 
Scale 0.00125† 0.0025† 0.005† 
Radius (Å) 119.844 115 113.546 
Length (Å) 39.2044 40.4 39.2046 
SLD cylinder (×10
-6
 Å
-2
) 2.78 3.16 3.16 
SLD solvent (×10
-6
 Å
-2
) 5.28† 5.28† 5.28† 
Incoherent background (cm
-1
) 0.0498† 0.0477† 0.0479† 
Figure A.2: Uniform cylinder model fits to CP1 in DMSO-d6
 
(
†
=held parameter value) 
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 CP1 (1 mM) in 
DMSO-d6 
CP1 (2 mM) in 
DMSO-d6 
CP1 (4 mM) in 
DMSO-d6 
Scale 0.00125† 0.0025† 0.005† 
Radius (Å) 86.3813 94.7 102.268 
Length (Å) 49.7466 48.5 43.0544 
Radial polydispersity
‡
 0.425417 0.31464 0.234273 
SLD cylinder (×10
-6
 Å
-2
) 2.95 3.27 3.22 
SLD solvent (×10
-6
 Å
-2
) 5.28† 5.28† 5.28† 
Incoherent background (cm
-1
) 0.0498† 0.0477† 0.0479† 
Figure A.3: Cylinder (polydisperse radius) model fits to CP1 in DMSO-d6
 
(
†
=held parameter value, 
‡
=Schultz polydispersity) 
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 CP1-(pBA30)2 (1 mM) 
in DMSO-d6 
CP1-(pBA30)2 (1 mM) 
in TFA-d 
Scale 0.01† 0.01† 
Ra (rotation axis) (Å) 40.0274 42.1733 
Rb (Å) 10.2849 14.8066 
SLD ellipsoid (×10
-6
 Å
-2
) 3.18 1.99 
SLD solvent (×10
-6
 Å
-2
) 5.28† 3.00† 
Incoherent background (cm
-1
) 0.0494† 0.0360† 
Figure A.4: Uniform ellipsoid model fits to CP1-(pBA30)2 in DMSO-d6 and TFA-d
 
(
†
=held parameter 
value) 
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 CP1-(pBA30)2 (1 mM) 
in DMSO-d6 
CP1-(pBA30)2 (1 mM) 
in TFA-d 
Scale 0.01† 0.01† 
Radius (Å) 9.56875 13.7479 
Length (Å) 59.7939 64.6893 
SLD cylinder (×10
-6
 Å
-2
) 3.16 1.98 
SLD solvent (×10
-6
 Å
-2
) 5.28† 3.00† 
Incoherent background (cm
-1
) 0.0494† 0.0360† 
Figure A.5: Uniform cylinder model fits to CP1-(pBA30)2 in DMSO-d6 and TFA-d
 
(
†
=held parameter 
value) 
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 CP1-(pBA30)2 (1 mM) 
in CDCl3 
CP1-(pBA30)2 (1 mM) 
in THF-d8 
Scale 0.01† 0.01† 
Radius (Å) 14.182 8.68885 
Length (Å) >1100 >1100 
SLD cylinder (×10
-6
 Å
-2
) 2.18 2.89 
SLD solvent (×10
-6
 Å
-2
) 3.16† 6.35† 
Incoherent background (cm
-1
) 0.0341† 0.0749† 
Figure A.6: Uniform cylinder model fits to CP1-(pBA30)2 in CDCl3 and THF-d8
 
(
†
=held parameter 
value) 
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 CP1-(pBA30)2 (1 mM) in 
TFA-d/CDCl3 (1:9 v/v) 
CP1-(pBA30)2 (1 mM) in 
TFA-d/CDCl3(9:1 v/v) 
Scale 0.01† 0.01† 
Radius (Å) 6.89908 12.2865 
Length (Å) 68.9042 64.504 
SLD cylinder (×10
-6
 Å
-2
) 1.54 1.97 
SLD solvent (×10
-6
 Å
-2
) 3.02† 3.14† 
Incoherent background (cm
-1
) 0.0387† 0.0404† 
Figure A.7: Uniform cylinder model fits to CP1-(pBA30)2 in TFA-d/CDCl3 (1:9 v/v, 9:1 v/v) (
†
=held 
parameter value) 
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 CP1-(pBA30)2 (1 mM) in 
TFA-d/THF-d8 (1:9 v/v) 
CP1-(pBA30)2 (1 mM) in 
TFA-d/THF-d8 (9:1 v/v) 
Scale 0.01† 0.01† 
Radius (Å) 8.29078 10.9282 
Length (Å) 285.967 67.5194 
SLD cylinder (×10
-6
 Å
-2
) 2.72 1.86 
SLD solvent (×10
-6
 Å
-2
) 6.02† 3.34† 
Incoherent background (cm
-1
) 0.0782† 0.047† 
Figure A.8: Uniform cylinder model fits to CP1-(pBA30)2 in TFA-d/THF-d8 (1:9 v/v, 9:1 v/v) (
†
=held 
parameter value) 
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 CP1-(pBA30)2 (1 mM) in 
TFA-d/THF-d8 (1:9 v/v) 
CP1-(pBA30)2 (1 mM) in 
TFA-d/THF-d8 (1:9 v/v)
*
 
Scale 0.01† 0.01† 
Radius (Å) 8.29078 6.79851 
Length (Å) 285.967 127.651 
SLD cylinder (×10
-6
 Å
-2
) 2.72 0.873 
SLD solvent (×10
-6
 Å
-2
) 6.02† 6.02† 
Incoherent background (cm
-1
) 0.0782† 0.0736† 
Figure A.9: Uniform cylinder model fits to CP1-(pBA30)2 in TFA-d/THF-d8 (1:9 v/v) where the 
asterisked sample was prepared by dissolving CP1-(pBA30)2 in TFA-d then diluted with THF-d8. 
(
†
=held parameter value) 
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 CP1-(pBA30)2 
(1 mM) in CDCl3 
CP3-(pBA30)2 
(1 mM) in CDCl3 
CP3-(pBA30)1.5 
(1 mM) in CDCl3 
Scale 0.01† 0.01† 0.01† 
Radius (Å) 14.182 12.4471 13.9855 
Length (Å) >1100 >300 >300 
SLD cylinder (×10
-6
 Å
-2
) 2.18 2.10 2.19 
SLD solvent (×10
-6
 Å
-2
) 3.16† 3.16† 3.16† 
Incoherent background (cm
-1
) 0.0341† 0.0368† 0.0361† 
Figure A.10: Uniform cylinder model fits to CP1-(pBA30)2, CP3-(pBA30)2 and CP3-(pBA30)1.5 in 
CDCl3. (
†
=held parameter value) 
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 CP2-(pBA30)2 
(1 mM) in CDCl3 
CP2-(pBA30)1.5 
(1 mM) in CDCl3 
Scale 0.01† 0.01† 
Radius (Å) 10† 10† 
Length (Å) 1100† 1100† 
Radial polydispersity
‡
 1.09517 0.931463 
SLD cylinder (×10
-6
 Å
-2
) 2.37 2.30 
SLD solvent (×10
-6
 Å
-2
) 3.16† 3.16† 
Incoherent background (cm
-1
) 0.037† 0.037† 
Figure A.11: Cylinder (polydisperse radius) model fits to CP2-(pBA30)2 and CP2-(pBA30)1.5 in 
CDCl3. (
†
=held parameter value, 
‡
=Schultz polydispersity) 
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A.2 Chapter 4 – (N-Methylated cyclic peptide)-polymer conjugates 
 
 
Figure A.12: Dilution of 
NMe
CP1-pBA16 in CHCl3. Pre-I2 treatment. 
 
 
Figure A.13: 
NMe
CP1-pBA16 in CHCl3 with addition of MeOH. 
 
 
Figure A.14: 
NMe
CP1-pBA16 in THF at 20 °C and 40 °C. 
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Figure A.15: 
NMe
CP1-pBA16 in THF pre- and post-I2 treatment. 
 
 
Figure A.16: 
NMe
CP1-pBA30 pre-I2 treatment at 20 °C and 40 °C. Lack of change suggests a 
scattering is not supramolecular and no meaningful scattering post-I2 treatment suggests the above 
profile is due to CuNPs. 
 
 
Figure A.17: Dilution of 
NMe
CP1-pSty20 in CHCl3. Pre-I2 treatment. 
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Figure A.18: 
NMe
CP1-pSty20 in CHCl3 with addition of MeOH. Pre-I2 treatment. 
 
 
Figure A.19: Dilution of 
NMe
CP1-pSty20 in THF. Pre-I2 treatment. 
 
 
Figure A.20: 
NMe
CP1-pSty20 pre-I2 treatment at 20 °C and 40 °C. At 0.2 mM the scattering profile 
disappears on heating. 
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Figure A.21: Dilution of 
NMe
CP1-pSty20 in CHCl3. Post-I2 treatment. Lack of significant difference 
owing itself to lack of CuNPs. 
 
 
Figure A.22: Dilution of 
NMe
CP1-pSty20 in THF. Post-I2 treatment. Lack of significant difference 
owing itself to lack of CuNPs formed. 
 
 
Figure A.23: Dilution of di
NMe
CP1-pBA22 in THF. Pre-I2 treatment. 
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Figure A.24: Dilution of di
NMe
CP1-pBA22 in CHCl3. Pre-I2 treatment. 
 
 
Figure A.25: di
NMe
CP1-pBA22 in CHCl3 with addition of MeOH. Pre-I2 treatment. 
 
 
Figure A.26: di
NMe
CP1-pBA22 pre-I2 treatment at 20 °C and 40 °C. At 0.01 mM, heating the sample 
removes the assembly. 
 
Appendix 
145 
 
 
Figure A.27: di
NMe
CP1-pBA22 in THF pre- and post-I2 treatment. 
 
 
Scale 0.0032
†
 
Radiusa (rotation axis) (Å) 36.3685 
Radiusb (Å) 8.04750 
SLD ellipsoid (×10
-6
 Å
-2
) 1.76 
SLD solvent (×10
-6
 Å
-2
) 6.35
†
 
Incoherent background (cm
-1
) 0.0718
†
 
Figure A.28: Fitting uniform (needle-like) ellipsoid model to 
NMe
CP1-pBA16 (1 mM). (
†
=held 
parameter value) 
  
Appendix 
146 
 
 
Scale 0.00664
†
 
Radiusa (rotation axis) (Å) 39.7283 
Radiusb (Å) 8.06666 
SLD ellipsoid (×10
-6
 Å
-2
) 1.81 
SLD solvent (×10
-6
 Å
-2
) 6.35
†
 
Incoherent background (cm
-1
) 0.0761
†
 
Figure A.29: Fitting uniform (needle-like) ellipsoid model to 
NMe
CP1-pBA16 (2 mM). (
†
=held 
parameter value) 
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Scale 0.0133
†
 
Radiusa (rotation axis) (Å) 40.2312 
Radiusb (Å) 8.33850 
SLD ellipsoid (×10
-6
 Å
-2
) 2.03 
SLD solvent (×10
-6
 Å
-2
) 6.35
†
 
Incoherent background (cm
-1
) 0.0836
†
 
Figure A.30: Fitting uniform (needle-like) ellipsoid model to 
NMe
CP1-pBA16 (4 mM). (
†
=held 
parameter value) 
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Scale 0.0035
†
 
Radiusa (rotation axis) (Å) 55.2026 
Radiusb (Å) 6.99171 
SLD ellipsoid (×10
-6
 Å
-2
) 1.84 
SLD solvent (×10
-6
 Å
-2
) 6.35
†
 
Incoherent background (cm
-1
) 0.0681
†
 
Figure A.31: Fitting uniform (needle-like) ellipsoid model to 
NMe
CP-pSty20 (1 mM). (
†
=held 
parameter value) 
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Scale 0.0067
†
 
Radiusa (rotation axis) (Å) 58.0159 
Radiusb (Å) 7.97441 
SLD ellipsoid (×10
-6
 Å
-2
) 2.27 
SLD solvent (×10
-6
 Å
-2
) 6.35
†
 
Incoherent background (cm
-1
) 0.0744
†
 
Figure A.32: Fitting uniform (needle-like) ellipsoid model to 
NMe
CP1-pSty20 (2 mM). (
†
=held 
parameter value) 
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Scale 0.0134
†
 
Radiusa (rotation axis) (Å) 61.1829 
Radiusb (Å) 8.6216 
SLD ellipsoid (×10
-6
 Å
-2
) 2.62 
SLD solvent (×10
-6
 Å
-2
) 6.35
†
 
Incoherent background (cm
-1
) 0.0805
†
 
Figure A.33: Fitting uniform (needle-like) ellipsoid model to 
NMe
CP1-pSty20 (4 mM). (
†
=held 
parameter value) 
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Scale 0.00996
†
 
Radius (Å) 5
†
 
Length (Å) 10.2
†
 
SLD cylinder (×10
-6
 Å
-2
) 2.98 
SLD solvent (×10
-6
 Å
-2
) 6.35
†
 
Incoherent background (cm
-1
) 0.0685
†
 
Figure A.34: Fitting dimer model to 
NMe
CP1 (1 mM). (
†
=held parameter value) 
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Scale 0.0199
†
 
Radius (Å) 5
†
 
Length (Å) 10.2
†
 
SLD cylinder (×10
-6
 Å
-2
) 3.73 
SLD solvent (×10
-6
 Å
-2
) 6.35
†
 
Incoherent background (cm
-1
) 0.0720
†
 
Figure A.35: Fitting dimer model to 
NMe
CP1 (2 mM). (
†
=held parameter value) 
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Scale 0.0398
†
 
Radius (Å) 5
†
 
Length (Å) 10.2
†
 
SLD cylinder (×10
-6
 Å
-2
) 3.91 
SLD solvent (×10
-6
 Å
-2
) 6.35
†
 
Incoherent background (cm
-1
) 0.0718
†
 
Figure A.36: Fitting dimer model to 
NMe
CP1 (4 mM). (
†
=held parameter value) 
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Scale 0.00996
†
 
Radius (Å) 8.79895 
SLD ellipsoid (×10
-6
 Å
-2
) 4.30
†
 
SLD solvent (×10
-6
 Å
-2
) 6.35
†
 
Incoherent background (cm
-1
) 0.0685
†
 
Figure A.37: Fitting uniform sphere model to 
NMe
CP (1 mM). (
†
=held parameter value) 
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Scale 0.0119
†
 
Radiusa (rotation axis) (Å) 22.6418 
Radiusb (Å) 6.58302 
SLD ellipsoid (×10
-6
 Å
-2
) 4.30
†
 
SLD solvent (×10
-6
 Å
-2
) 6.35
†
 
Incoherent background (cm
-1
) 0.0681
†
 
Figure A.38: Fitting uniform (needle-like) ellipsoid model to 
NMe
CP (2 mM). (
†
=held parameter 
value) 
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Scale 0.0398
†
 
Radiusa (rotation axis) (Å) 32.5277 
Radiusb (Å) 4.26526 
SLD ellipsoid (×10
-6
 Å
-2
) 4.30
†
 
SLD solvent (×10
-6
 Å
-2
) 6.35
†
 
Incoherent background (cm
-1
) 0.0718
†
 
Figure A.39: Fitting uniform (needle-like) ellipsoid model to 
NMe
CP (4 mM). (
†
=held parameter 
value) 
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A.3 Chapter 5 – ‘Capped’ nanotubes 
In the isodesmic growth of ditopic units A, from successive equilibria equations between 
monomers and i-mers, the following can be written:
[196]
 
 
[  ]  [ ]
 ∏   
 
   
     [  ]
  (A.1) 
 
Where [Ai] is the concentration of ditopic assembly consisting of i ditopic units, [A] is the 
concentration ditopic unit in monomeric form, Ki is the equilibrium constant of the addition 
of i ditopic units.  
We consider the addition of monotopic species B which can interact with A and/or 
another unit of B, then we have the following: 
 [  ]      [ ]
  (A.2) 
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  (A.4) 
 
Where [B] and [BB] is the concentration of unimers and dimers of monotopic species 
with an association constant Kdim, and [AiB] and [BAiB] is the concentration of one and two 
monotopic species associating with Ai with equilibrium constant KB. 
Establishing the inventory of material, the total concentration of A, AT is given by: 
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(A.5) 
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The total concentration of B, BT is given by: 
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(A.6) 
 
The total concentration of free monotopic units Bfree is given by: 
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  (A.7) 
 
Now we establish the inventory of nanotubes. NT is the total concentration of all 
nanotubes: 
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(A.8) 
 
NA only is the concentration of nanotubes where B and BB are excluded from this 
definition: 
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(A.9) 
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NB free is the concentration of monomers and dimers of B: 
 
        [ ]  [  ]
 [ ]      [ ]
  (A.10) 
 
Having established the inventory, we then calculate the averages. The number average 
degree of polymerisation <DP>n is given by: 
 
〈  〉  
     
  
 (A.11) 
 
The number distribution of ditopic species <A>n-A only which intentionally neglects B and 
BB as nanotubes: 
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 (A.12) 
 
Similarly, the number distribution of monotopic species unassociated with ditopic 
species, given as <B>n-B free: 
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 (A.13) 
 
Equation (A.5) can be rewritten as: 
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Substituting (A.14) into (A.6): 
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Microsoft Excel 2010 Solver was used to numerically solve for [A] when f([A], AT, BT, K, 
KB, Kdim) = 0. 
The following (Microsoft Visual Basic for Applications 7.0) Macros were written and 
used to find the solutions of 200 values: 
Sub Macro1()    'Coarse precision 
    SolverOptions MaxTime:=0, Iterations:=0, Precision:=0.00001, Convergence:= _ 
        0.0001, StepThru:=False, Scaling:=True, AssumeNonNeg:=True, Derivatives:=2 
    SolverOptions PopulationSize:=100, RandomSeed:=0, MutationRate:=0.075, 
Multistart _ 
        :=False, RequireBounds:=True, MaxSubproblems:=0, MaxIntegerSols:=0, _ 
        IntTolerance:=1, SolveWithout:=False, MaxTimeNoImp:=30 
For i = 2 To 201 Step 1 
    SolverReset 
    SolverOk SetCell:="$B" + CStr(i), MaxMinVal:=3, ValueOf:=0, ByChange:="$C" + 
CStr(i), Engine:=1 _ 
        , EngineDesc:="GRG Nonlinear" 
    SolverAdd CellRef:="$D" + CStr(i), Relation:=1, FormulaText:="$F" + CStr(i) 
    SolverSolve 
Next i 
End Sub 
Appendix 
161 
 
Sub Macro2()    'Fine precision 
    SolverOptions MaxTime:=0, Iterations:=0, Precision:=0.000000001, Convergence:= _ 
        0.0001, StepThru:=False, Scaling:=True, AssumeNonNeg:=True, Derivatives:=2 
    SolverOptions PopulationSize:=100, RandomSeed:=0, MutationRate:=0.075, 
Multistart _ 
        :=False, RequireBounds:=True, MaxSubproblems:=0, MaxIntegerSols:=0, _ 
        IntTolerance:=1, SolveWithout:=False, MaxTimeNoImp:=30 
For i = 2 To 8 Step 1 
    SolverReset 
    SolverOk SetCell:="$B" + CStr(i), MaxMinVal:=3, ValueOf:=0, ByChange:="$C" + 
CStr(i), Engine:=1 _ 
        , EngineDesc:="GRG Nonlinear" 
    SolverAdd CellRef:="$D" + CStr(i), Relation:=1, FormulaText:="$F" + CStr(i) 
    SolverSolve 
Next i 
End Sub 
Where $B refers to f([A], AT, BT, K, KB, Kdim)×10
5
 
$C refers to [A]×10
9
 
$D refers to [A] 
$F refers to AT 
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The arbitrary multiplication of f([A], AT, BT, K, KB, Kdim) and [A] was used to circumvent 
the limitations of Microsoft Excel. The constraint [A] ≤ AT was used. K, KB, Kdim were kept 
constant. BT was directly proportional to AT by a constant factor (determined by the fraction 
of monotopic species). With AT as the independent variable, [A] was analytically solved from 
the (non-cap) model of Moore et al.
[196]
, then used for the initial values for the Solver routine.  
To describe the end-functionality of the nanotubes, we consider the number of non-, 
mono- and di- end-functional nanotubes (N0fn, N1fn, N2fn respectively) in relation to the total 
number of ‘A only nanotubes’ NA only: 
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Figure A.40: Population of non-, mono- and di- end-functional nanotubes as a function of 
concentration. Where black lines represent the case where associations are equal. Blue lines represent 
the case when KB is significantly greater that K, the same blue traces are observed if KB = 4×10
9
 M
-1
 
but Kdim = 2000 M
-1
. 
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Figure A.41: Population of non-, mono- and di- end-functional nanotubes as a function of 
concentration for fractions of monotopic species of: 10 % (black lines) and 80 % (blue lines). 
 
 
 
